0001683168-19-001220.txt : 20190429 0001683168-19-001220.hdr.sgml : 20190429 20190429135027 ACCESSION NUMBER: 0001683168-19-001220 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 42 CONFORMED PERIOD OF REPORT: 20180930 FILED AS OF DATE: 20190429 DATE AS OF CHANGE: 20190429 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Dougherty's Pharmacy, Inc. CENTRAL INDEX KEY: 0001080029 STANDARD INDUSTRIAL CLASSIFICATION: RETAIL-DRUG STORES AND PROPRIETARY STORES [5912] IRS NUMBER: 752900905 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-27945 FILM NUMBER: 19775058 BUSINESS ADDRESS: STREET 1: 5924 ROYAL LANE, SUITE 250 CITY: DALLAS STATE: TX ZIP: 75230 BUSINESS PHONE: 972-250-0945 MAIL ADDRESS: STREET 1: 5924 ROYAL LANE, SUITE 250 CITY: DALLAS STATE: TX ZIP: 75230 FORMER COMPANY: FORMER CONFORMED NAME: ASCENDANT SOLUTIONS INC DATE OF NAME CHANGE: 20001023 FORMER COMPANY: FORMER CONFORMED NAME: ASD SYSTEMS INC DATE OF NAME CHANGE: 19990713 10-Q 1 dougherty_10q.htm FORM 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

(Mark one)

☒

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2018

☐

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission file number: 000-27945

DOUGHERTY’S PHARMACY, INC.

(Exact name of registrant as specified in its charter)

Delaware	75-2900905
(State or other jurisdiction	(I.R.S. Employer
of incorporation or organization)	Identification No.)

5924 ROYAL LANE SUITE 250

DALLAS, TEXAS 75230

(Address of principal executive offices) (Zip code)

972-250-0945

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☐ No ☒

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☐ No ☒

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one)

Large accelerated filer ☐	Accelerated filer ☐
Non-accelerated filer ☐	Smaller reporting company ☒
	Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

Number of shares of common stock, $0.0001 par value, of registrant outstanding at April 22, 2019: 24,127,914.

TABLE OF CONTENTS

		Page
PART I. FINANCIAL INFORMATION		3

Item 1.	FINANCIAL STATEMENTS	3

	Consolidated Balance Sheets as of September 30, 2018 and December 31, 2017	3

	Consolidated Statements of Operations for the Three and Nine Months ended September 30, 2018 and 2017	4

	Consolidated Statements of Cash Flows for the Nine Months ended September 30, 2018 and 2017	5

	Notes to Consolidated Financial Statements	6

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	13

Item 4.	Controls and Procedures	19

PART II. OTHER INFORMATION		20

Item 1.	Legal Proceedings	20

Item 3.	Default on Senior Securities	20

Item 6.	Exhibits	20

SIGNATURES		21

PART I – FINANCIAL INFORMATION

Item 1. Financial Statements

Dougherty’s Pharmacy, Inc.

Consolidated Balance Sheets

(000’s omitted, except par value and share amounts)

	September 30,			December 31,
	2018			2017
	(Unaudited)			(Audited)
ASSETS

Current Assets
Cash	$	206		$	86
Restricted cash		–			303
Trade accounts receivable, net		1,585			1,673
Other receivables		218			345
Receivable from affiliates		–			6
Inventories, net		2,854			3,562
Prepaid expenses		77			267
Total current assets		4,940			6,242
Long term receivable		472			448
Property and equipment, net		956			1,045
Intangible assets, net		2,389			2,892
Deferred tax asset		–			2,000
Total assets	$	8,757		$	12,627

LIABILITIES

Current Liabilities
Accounts payable	$	2,896		$	3,123
Accrued liabilities		483			429
Notes payable, current portion		1,326			813
Revolving credit facility		3,956			3,831
Total current liabilities		8,661			8,196
Notes payable, long-term portion		1,653			2,801
Total liabilities		10,314			10,997

STOCKHOLDERS' EQUITY

Stockholders' equity:
Preferred stock, $0.0001 par value; 7,500,000 shares authorized: none issued and outstanding
Common stock, $0.0001 par value; 50,000,000 shares authorized; 24,112,164 shares issued and 23,082,164 shares outstanding at September 30, 2018; 24,003,310 shares issued and 22,973,310 shares outstanding at December 31, 2017		2			2
Additional paid-in capital		60,214			60,221
Accumulated deficit		(61,376	)		(58,196	)
Treasury stock, at cost, 1,030,000 shares		(397	)		(397	)
Total stockholders' equity		(1,557	)		1,630
Total liabilities and stockholders' equity	$	8,757		$	12,627

See Notes to Consolidated Financial Statements

Dougherty’s Pharmacy, Inc.

Consolidated Statements of Operations

(000’s omitted, except share and per share amounts)

(Unaudited)

	Three Months Ended						Nine Months Ended
	September 30,						September 30,
	2018			2017			2018			2017

Revenue	$	8,761		$	9,947		$	27,384		$	30,213
Cost of sales (exclusive of depreciation and amortization shown separately down below)		6,650			7,367			20,431			22,083
Gross profit		2,111			2,580			6,953			8,130

Operating expenses
Selling, general and administrative expenses		2,285			2,632			7,233			7,820
Non-cash stock compensation		1			11			(6	)		26
Depreciation and amortization		231			249			713			769
Total operating expenses		2,517			2,892			7,940			8,615
Operating loss		(406	)		(312	)		(987	)		(485	)

Other income		47			–			135			–
Interest income		–			–			33			–
Interest expense		(118	)		(115	)		(339	)		(317	)
Loss on disposal of assets and investment impairment		–			–			–			(75	)
Loss before provision for income tax		(477	)		(427	)		(1,158	)		(877	)
Income tax provision		(2,006	)		(9	)		(2,022	)		(32	)
Net loss	$	(2,483	)	$	(436	)	$	(3,180	)	$	(909	)


Basic and diluted net loss per share attributable to common stockholders	$	(0.11	)	$	(0.02	)	$	(0.14	)	$	(0.04	)
Weighted-average number of shares-basic and diluted		23,097,914			22,476,821			23,087,347			22,450,017

See Notes to Consolidated Financial Statements

Dougherty’s Pharmacy, Inc.

Consolidated Statements of Cash Flows

(000’s omitted)

(Unaudited)

	Nine Months Ended September 30,
	2018			2017

Operating Activities
Net loss	$	(3,180	)	$	(909	)
Items not requiring (providing) cash
Loss from disposal of assets		–			75
Provision for doubtful accounts		–			6
Depreciation and amortization		713			769
Change in deferred tax asset		2,000			–
Stock-based compensation		(7	)		26
Changes in operating assets and liabilities:
Accounts receivable		197			94
Inventories		708			(193	)
Prepaid expenses and other assets		190			12
Accounts payable		(227	)		388
Accrued liabilities		54			334
Net cash provided by operating activities		448			602

Investing Activities
Purchases of property and equipment		(121	)		(85	)
Cash received upon disposition of pharmacy		–			274
Cash received upon disposition of CPOC		–			688
Net (used in) provided by investing activities		(121	)		877

Financing Activities
Payments on notes payable		(8,561	)		(15,735	)
Proceeds from notes payable		8,051			14,345
Net cash used in financing activities		(510	)		(1,390	)

Net (decrease) increase in cash		(183	)		89

Cash, beginning of period		389			361
Cash, end of period	$	206		$	450

Supplemental Cash Flow Information
Cash paid for income taxes	$	24		$	42
Cash paid for interest	$	336		$	315

Reconciliation of Cash to the Consolidated Balance Sheets
Cash	$	206		$	147
Restricted cash		–			303
Total cash	$	206		$	450

See Notes to Consolidated Financial Statements

Dougherty’s Pharmacy, Inc.

Notes to Consolidated Financial Statements

1. Organization and Significant Accounting Policies

Description of Business

Dougherty’s Pharmacy, Inc. (“Dougherty’s” or the “Company”) is a value-oriented company focused on successfully acquiring, managing and growing community-based pharmacies in the Southwest Region. Dougherty’s was incorporated in Delaware on August 8, 2000.

A summary of the Company’s investments at September 30, 2018, is shown in the table below:

Date	Entity	Transaction Description	% Ownership

March 2004	Dougherty’s Holdings, Inc. and subsidiaries (“DHI”or “the Borrowers”)	Acquisition of retail pharmacy		100%

September 2010	ASDS of Orange County, Inc. (“ASDS”),	Holding company for Investment in CRESA Partners of Orange County, L.P. (“CPOC”)		100%

On February 7, 2017, CRESA Partners of Orange County, L.P., an affiliate of Cresa Partners-West, Inc. was acquired by Savills Studley, Inc. liquidating the partnership interest in its entirety held by ASDS. ASDS remains active as a holding company for the remaining payouts.

On May 6, 2017, the Company sold its pharmacy in Humble, Texas, acquired in September 2014, and received total cash proceeds of $274,000 related to this transaction. The revenues and earnings of the pharmacy are not significant to the consolidated financial statements taken as a whole.

On February 6, 2018, the Company opened a new retail pharmacy location at The Campus at Legacy West in Plano, Texas (“Legacy”). This new location will offer pharmacy services and retail products to approximately 3,000 JCPenney Home Office employees and will be open to all other future tenants and visitors of The Campus at Legacy West. Dougherty’s is initially filling prescriptions via concierge service from its pharmacy on Campbell Road until Legacy completes its third-party contract enrollment process. The first year revenues for this location were less than $150,000. The location was closed on February 7, 2019.

Our business has historically required us to rely on cash flow from operations and upon borrowing under a $4,000,000 revolving credit facility (“the Revolver”) with the First National Bank of Omaha (the “Lender”) as our primary sources of funding to operate and meet our financial obligations. Historically, much of our debt, including the Revolver, has been renewed or refinanced in the ordinary course of business. However, on August 1, 2018, the Company was obligated to make payment of the outstanding principal of $3,956,000 plus $18,000 in accrued and unpaid interest under the Revolver. Failure to make this payment on the August 1, 2018, maturity date was an event of default under the Revolver. The accrued interest of $18,000 was paid on August 2, 2018. An event of default under the Revolver permits the Lender, among other things, to foreclose on the assets securing the Revolver, which includes certain retail pharmacy assets, specifically but not limited to, inventory, equipment, software, accounts receivable, intangibles and deposit accounts of the Company (the “Secured Assets”). In addition to the failure to make the payment on the maturity date, as of August 1, 2018, the Company was not in compliance with its covenant to maintain a minimum debt service coverage ratio of not less than 1.00 to 1.00, as defined under the Revolver. Failure to maintain this financial covenant also constitutes an event of default under the Revolver. In light of these uncertainties, Management cannot provide any assurance that it can fund the Company’s capital needs in the near or long term.

On August 10, 2018, the Lender notified the Company that the Revolver had been sold to OSK VII, LLC (the “Current Lender”) effective on August 10, 2018. This assignment of the Revolver from the Lender to the Current Lender does not affect any terms and condition of the Revolver and the associated loan documents. The Company does not currently have the ability to cure either events of default under the Revolver. Should the Current Lender elect to foreclose against the Secured Assets, it would significantly impair the Company's ability to continue as a going concern or to even be able to continue its operations. The Company is evaluating all of its options in light of these circumstances, including, without limitation, refinancing the indebtedness with another lender, negotiating a settlement arrangement with the Current Lender, or obtaining a temporary waiver or forbearance from the Current Lender; provided, however, the Company can provide no assurances that any of these arrangements can be entered into or if entered into would be upon terms and conditions beneficial to and acceptable by the Company. In light of these uncertainties, Management cannot provide any assurance that it can fund the Company’s capital needs in the near or long term.

We have historically maintained a level of liquidity sufficient to allow us to cover our cash needs in the short-term. Over the long-term, we have managed our cash and capital structure to maintain our financial position and maintain flexibility for future strategic initiatives. We continuously assess our working capital needs, debt and leverage levels, capital expenditure requirements, and future investments or acquisitions. As of September 30, 2018, we had cash of approximately $206,000, working capital deficit of $3,720,000 and total outstanding debt of $6,935,000. Cash provided from operating activities for the nine months ended September 30, 2018 was $448,000.

On March 22, 2019, the Company secured a letter of credit in the amount of $825,000 issued by Legacy Texas Bank for the benefit of Associated Food Stores, Inc. that renews annually with a reduction of $100,000 on each anniversary date.

Significant Accounting Policies

Basis of Presentation

The consolidated financial statements include the accounts of Dougherty’s and all subsidiaries for which the Company has a controlling financial interest. Dougherty’s uses the cost method of accounting to recognize investments in and income from entities where Dougherty’s does not have a significant influence. All intercompany balances and transactions have been eliminated in consolidation. The accompanying unaudited consolidated financial statements of the Company and its wholly owned subsidiaries have been prepared by the Company, in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and are presented in accordance with the requirements of Form 10-Q and Rule 10-01 of Regulation S-X and have not been audited. Accordingly, these unaudited consolidated financial statements do not include all of the information and notes required by GAAP for complete financial statements and should be read in conjunction with the audited consolidated financial statements and notes thereto for the fiscal year ended December 31, 2017 included in the Company’s Form 10-K. In the opinion of management, the interim unaudited consolidated financial statements included herein contain all adjustments, including normal recurring adjustments, considered necessary to present fairly the Company’s financial position, the results of operations and cash flows for the periods presented. Due to seasonality, the results of operations for the nine months ended September 30, 2018, are not necessarily indicative of the results to be expected for any future interim period for the year ending December 31, 2018.

Use of Estimates

The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Concentration of Credit Risk

The Company’s credit risk relates primarily to its trade accounts receivables and its receivables from affiliates, along with cash deposits maintained at financial institutions in excess of federally insured limits on interest bearing accounts. Management performs continuing evaluations of debtors’ financial condition and maintains an allowance for uncollectible accounts as determined necessary.

Accounts Receivable

Receivables recorded in the financial statements represent valid claims against debtors for services rendered or other charges arising on or before the balance sheet date. Management makes estimates of the collectability of accounts receivable. Specifically, management analyzes accounts receivable and historical bad debts, customer credit-worthiness, current economic trends, and changes in customer payment terms and collections trends when evaluating the adequacy of the allowance for doubtful accounts. Any change in the assumptions used in analyzing accounts receivable may result in additional allowances for doubtful accounts being recognized in the periods in which the change in assumptions occurs.

At September 30, 2018 and 2017, all of the trade accounts receivable were from retail pharmacy operations.

Inventories

Inventories consist of health care product finished goods held for resale, valued at the lower of cost using the first-in, first-out method or net realizable value. The Company maintains an estimated reserve against inventory for excess, slow-moving, and obsolete inventory as well as inventory for which carrying value is in excess of its net realizable value.

Long-Lived Assets

The Company evaluates the recoverability of the carrying value of its long-lived assets whenever events or circumstances indicate the carrying amount may not be recoverable. If a long-lived asset is tested for recoverability and the undiscounted estimated future cash flows expected to result from the use and eventual disposition of the asset is less than the carrying amount of the asset, the asset cost is adjusted to fair value and an impairment loss is recognized as the amount by which the carrying amount of a long-lived asset exceeds its fair value.

Revenue Recognition

Revenues generated by the retail pharmacy operations are reported at the estimated net realizable amounts expected to be received from individuals, third-party payors, institutional health care providers and others. The Company recognizes revenue from the sale of pharmaceutical products and retail merchandise as transactions occur and product is delivered to the customer. Revenue from product sales is recognized at the point of sale and service revenue is recognized at the time services are provided.

Sales and similar taxes collected from clients are excluded from revenues. The obligation is included in accounts payable until the taxes are remitted to the appropriate taxing authorities.

Substantially all revenues earned during the nine months ended September 30, 2018 and 2017, were earned from the retail pharmacy operations.

Cost of Sales

Cost of sales includes the purchase price of goods sold, prescription packaging, compounded prescription direct labor, inventory obsolescence, freight costs, cash discounts and vendor rebates. Rebates or refunds received by the Company from its suppliers are considered as an adjustment of the prices of the supplier’s products purchased by the Company.

Income Taxes

The Company accounts for income taxes in accordance with income tax accounting guidance (ASC 740, Income Taxes). The income tax accounting guidance results in two components of income tax expense: current and deferred. Current income tax expense reflects taxes to be paid or refunded for the current period by applying the provisions of the enacted tax law to the taxable income or excess of deductions over revenues. The Company determines deferred income taxes using the liability (or balance sheet) method. Under this method, the net deferred tax asset or liability is based on the tax effects of the differences between the book and tax bases of assets and liabilities, and enacted changes in tax rates and laws are recognized in the period in which they occur. Deferred income tax expense results from changes in deferred tax assets and liabilities between periods. Deferred tax assets are reduced by a valuation allowance if, based on the weight of evidence available, it is more-likely-than-not that some portion or all of a deferred tax asset will not be realized.

Tax positions are recognized if it is more-likely-than-not, based on the technical merits, that the tax position will be realized or sustained upon examination. The term more-likely-than-not means a likelihood of more than 50%; the terms examined and upon examination also include resolution of the related appeals or litigation processes, if any. A tax position that meets the more-likely-than-not recognition threshold is initially and subsequently measured as the largest amount of tax benefit that has a greater than 50% likelihood of being realized upon settlement with a taxing authority that has full knowledge of all relevant information. The determination of whether or not a tax position has met the more-likely-than-not recognition threshold considers the facts, circumstances and information available at the reporting date and is subject to management’s judgment.

On December 22, 2017, the President signed into law the “Tax Cuts and Jobs Act” (the “TCJA”). Among numerous changes to existing tax laws, the TCJA permanently reduces the federal corporate income tax rate from 35% to 21% effective January 1, 2018. The effects on deferred tax balances of changes in tax rates are required to be taken into consideration in the period in which the changes are enacted, regardless of when they are effective. As the result of the reduction of the corporate income tax rate under the TCJA, the Company estimated the revaluation of its net deferred tax assets and recorded a provisional noncash income tax loss of approximately $1.0 million for year ended December 31, 2017. As of September 30, 2018, the Company fully reserved its deferred tax asset resulting in a $2 million charge to the income statement due to uncertainty of future income to utilize such assets.

Earnings per Share

Basic earnings per share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted earnings per share is computed by dividing net loss and unrecognized stock-based compensation by the weighted-average number of common shares outstanding during the period and the unvested restricted stock units. The unrecognized stock-based compensation as of September 30, 2018 and 2017 is $12,000 and $116,000, respectively; the unvested restricted stock units are 140,000 and 658,500, respectively. Due to the net losses for both years, restricted stock units for 2018 and 2017 were anti-dilutive.

New Accounting Pronouncements

ASU No. 2016-02, Leases (Topic 842)

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) ("ASU 2016-02"). ASU 2016-02 requires the lessee to recognize assets and liabilities for leases with lease terms of more than twelve months. For leases with a term of twelve months or less, the Company is permitted to make an accounting policy election by class of underlying asset not to recognize lease assets and lease liabilities. Further, the lease requires a finance lease to recognize both an interest expense and an amortization of the associated expense. Operating leases generally recognize the associated expense on a straight-line basis. ASU 2016-02 requires the Company to adopt the standard using a modified retrospective approach and becomes effective on January 1, 2019. The Company is currently evaluating the impact that ASU 2016-02 will have on its financial position, results of operations and cash flows. Our current minimum lease commitments are disclosed in Note 4.

2. Notes Payable

Notes payable consist of the following:

	September 30, 2018			December 31, 2017
		(Unaudited)			(Audited)

First National Bank of Omaha Credit Facility and Promissory Note secured by certain retail pharmacy assets
Revolving line of credit in the principal amount of $4,000,000 and $4,450,000, interest at LIBOR plus 3.25% (5.24% at September 30, 2018)	$	–		$	3,831,000
Term note OSK VII, LLC principal amount of $3,956,000, interest at LIBOR plus 3.25% (5.36% at September 30, 2018)		3,956,000
Term note in the principal amount of $432,859 at fixed interest rate of 8.11% per annum payable in 36 monthly installments of $13,641. Final payment plus accrued and unpaid interest due in full on April 10, 2020.		242,000			335,000
Term note in the principal amount of $1,827,850 with interest payable at prime plus 2.60% (7.85% at September 30, 2018) per annum payable in monthly installments of $15,232 plus interest, a final payment of $929,157 plus all accrued and unpaid interest due in full on July 10, 2020.		1,249,000			1,371,000
Term note in the principal amount of $1,241,350 with interest payable at prime plus 2.60% (7.85% at September 30, 2018) per annum payable in monthly installments of $10,344 plus interest, a final payment of $638,850 plus all accrued and unpaid interest due in full on January 10, 2020.		786,000			869,000
Term note in the principal amount of $744,100 with interest payable at prime plus 2.38% (7.63% at September 30, 2018) per annum payable in monthly installments of $6,200 plus interest, a final payment of $378,251 plus all accrued and unpaid interest due in full on August 10, 2020.		521,000			570,000
Term note in the principal amount of $305,350 with interest payable at prime plus 2.40% (7.65% at September 30, 2018) per annum payable in monthly installments of $2,545 plus interest, a final payment of $155,220 plus all accrued and unpaid interest due in full on August 10, 2019.		181,000			202,000
Acquisition Notes Payable, unsecured
Notes payable to sellers of acquired pharmacies with varying monthly payments with interest at 5.5% due through September 2018.		–			97,000
Insurance notes payable, secured by the respective insurance policies
Notes payable for the Company’s insurance policy premiums with varying monthly payments due through September 2018. Interest rates vary up to 4.076%		–			170,000
		6,935,000			7,445,000
Less current portion		(5,282,000	)		(4,644,000	)
	$	1,653,000		$	2,801,000

Future maturities of notes payable at September 30, 2018, are as follows:

2018	$	4,130,000
2019		1,324,000
2020		1,481,000
	$	6,935,000

The revolving credit facility (“the Revolver”) with the First National Bank of Omaha (“the Lender”) is secured by, but not limited to, the accounts receivable, inventory, and the fixed assets of the Borrowers. On July 1, 2017, the Company obtained an extension of the Revolver, through September 1, 2017. On August 9, 2017, the Company obtained an additional term for the Revolver in the amount of $4,450,000 effective September 1, 2017, and then effective February 1, 2018, in the amount of $4,000,000. Outstanding advances under the Revolver bore interest at LIBOR plus 3.25% (5.36% at September 30, 2018); accrued and unpaid interest on the Revolver was due monthly. All outstanding principal under the Revolver plus all accrued and unpaid interest thereon was due and payable in full on August 1, 2018 (See Note 6). On August 10, 2018, the Lender notified the Company that the Revolver had been sold to the Current Lender effective on August 10, 2018. This assignment of the Revolver from the Lender to the Current Lender does not affect any terms and condition of the Revolver and the associated loan documents. The Revolver is secured by certain retail pharmacy assets, specifically but not limited to, inventory, equipment, software, accounts receivable, intangibles and deposit accounts of the Company. The Revolver is subject to certain financial restrictions, now subject to the Current Lender’s prior written approval, including, but not limited to, capital expenditures not to exceed $200,000, additional indebtedness, acquisitions of entities and payment of dividends and distributions. Effective December 31, 2017, the Borrowers agreed to maintain a minimum debt service coverage ratio of not less than 1.00 to 1.00, as defined. As of September 30, 2018, the Borrowers were not in compliance with this financial covenant.

3. Stock and Share-Based Compensation

Restricted Share Unit Incentive Plan

On November 13, 2013, the Board of Directors approved and adopted the Restricted Share Unit (“RSU”) Incentive Plan. Under the plan the Company can award RSUs to employees and non-employee directors and consultants pursuant to restricted stock agreements contingent upon continuous service. Under the restricted stock agreements, the restricted shares will vest annually over a four-year period and will be payable in stock, valued at the fair market value on the grant date.

As of September 30, 2018, the following shares had been issued under the 2013 RSU Plan:

Year of Issuance:	Number of Shares		Fair Value at Date of Grant		Shares Vested		Non-Vested		Cancelled
2013		120,000	$	26,000		115,000		–		5,000
2014		122,100	$	31,000		101,850		–		20,250
2015		150,000	$	39,000		85,000		15,000		50,000
2016		–		–		–		–		–
2017		563,000	$	114,000		111,600		45,000		406,400
2018		80,000	$	11,000		–		80,000		–
		1,035,100	$	221,000		413,450		140,000		481,650

4. Commitments and Contingencies

Operating Leases

The Company leases their pharmacy, corporate offices and certain pharmacy equipment under non-cancelable operating lease agreements. Certain leases contain renewal options and provide that the Company pay taxes, insurance, maintenance and other operating expenses.

Minimum lease payments under all non-cancelable operating lease agreements for the nine months ended September 30, 2018, are as follows:

2018	$	788,000
2019		806,000
2020		670,000
2021		674,000
2022		685,000
Thereafter		3,372,000
	$	6,995,000

Legal Proceedings

The Company is occasionally involved in other claims and proceedings, which are incidental to its business. It is the opinion of management that the disposition or ultimate resolution of such claims and lawsuits will not have a material adverse effect on the consolidated financial position, results of operations and cash flows of the Company.

5. Related Party Transactions

During the three and nine months ended September 30, 2018, the Company paid fees to its directors of $5,000 and $33,000 for their roles as members of the Board of Directors and its related committees; fees paid to the Company’s Chairman totaled $30,000 and $90,000 for management and other services provided.

6. Subsequent Events

The Legacy West Campus in Plano, Texas was closed on February 4, 2019.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operation

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required under applicable securities laws.

The forward-looking statements contained in this Form 10-Q and other documents that we file or furnish with the SEC contain forward-looking statements that are based on current expectations, estimates, forecasts and projections about our future performance, our business, our beliefs and our management’s assumptions. In addition, we, or others on our behalf, may make forward-looking statements in press releases or written statements, on the Company’s website or in our communications and discussions with investors and analysts in the normal course of business through meetings, webcasts, phone calls, conference calls and other communications.

Statements that are not historical facts are forward-looking statements, including, without limitation, those regarding estimates of and goals for future financial and operating performance as well as forward-looking statements concerning the expected execution and effect of our business strategies. Words such as “expect,” “likely,” “outlook,” “forecast,” “preliminary,” “would,” “could,” “should,” “can,” “will,” “project,” “intend,” “plan,” “goal,” “guidance,” “continue,” “sustain,” “synergy,” “believe,” “seek,” “estimate,” “anticipate,” “may,” “possible,” “assume,” and variations of such words and similar expressions are intended to identify such forward-looking statements.

These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions, known or unknown, that could cause actual results to vary materially from those indicated or anticipated, including, but not limited to the following:

	·	Management cannot provide any assurance that it can fund the Company’s capital needs in the near or long-term.
	·	We are in default under our revolving credit facility, which jeopardizes our ability to continue current operations in the event that the lender elects to foreclose against the Company’s material assets securing this indebtedness;
	·	We have limited funds and will require additional financing to maintain our current operations;
	·	We have material weaknesses in our internal controls over financial reporting;
	·	Our disclosure controls are not effective;
	·	We may not be able to effectively integrate and manage our current and anticipated growth strategies;
	·	We could be subject to unforeseen costs associated with our Pharmacy Acquisitions which could reduce our profitability;
	·	We may enter into additional leveraged transactions in connection with future Pharmacy Acquisitions;
	·	We are substantially dependent on a single supplier of pharmaceutical products;
	·	We must maintain sufficient sales to qualify for favorable pricing under our long-term supply contract;
	·	We may be affected by the introduction of new brand name and generic prescription drugs, the conversion rate and mix of prescriptions filled, the reimbursement rate by third party payors of prescriptions and increases in the cost to procure those drugs;
	·	We are subject to considerable uncertainty as to how current Health Reform Laws will affect our business and operations;
	·	We could be negatively affected by future legislative or regulator policies designed to manage healthcare costs or alter healthcare financing practices; and
	·	We handle confidential healthcare information for our customers and are subject to the risk in securing such confidential information and protecting it from cyber-attacks.

These and other risks, assumptions and uncertainties include, but are not limited to, those factors described in the “Risk Factors” sections of our Registration Statement on Annual Report on Form 10-K filed on March 29, 2018. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated or anticipated by such forward-looking statements. Accordingly, you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. Except to the extent required by law, we do not undertake, and expressly disclaim, any duty or obligation to update publicly any forward-looking statement after the date the statement.

OVERVIEW

Key measures used by the Company’s management to evaluate business performance include revenue, gross profit, selling, general and administrative expense (“SG&A”) and EBITDA. EBITDA is calculated as net income before deducting interest, taxes, depreciation and amortization. EBITDA is a non-GAAP measure that the Company’s management considers to best present the results of ongoing operations and is useful when comparing the performance between different reporting periods. In those instances, we have identified when the Company is presenting adjusted EBITDA. Although EBITDA is not a measure of actual cash flow because it does not consider changes in assets and liabilities that may impact cash balances, the Company believes it is a useful metric to evaluate operating performance and has therefore included such measures in the discussion of operating results below.

The Company also tracks prescriptions sold to assess operational performance.

Overview of Our Business

Dougherty’s Pharmacy, Inc. (“Dougherty’s,” which is also referred to in this Quarterly Report on Form 10-Q as “we,” “us,” or “the Company”) is a value-oriented company focused on successfully acquiring, managing and growing community-based pharmacies in the Southwest Region. Our wholly owned subsidiary, Dougherty’s Holdings, Inc., owns and operates multiple Dougherty’s Pharmacies, which we operate as a single segment in our financial reporting. The flagship store, Dougherty’s Pharmacy, is a turn-key multi-service pharmacy located in a highly prestigious area of Dallas, Texas. Centrally located, we believe that Dougherty’s Pharmacy continues to provide a level of service not typically provided by national pharmacy chain stores. We fulfill virtually any prescription need, from the simplest to the most complex compounding prescriptions. Most national pharmacy chains do not provide complex pharmacy prescription services. We specialize in providing solutions for our retail customers’ pharmacy needs and also for our customers residing in assisted living facilities. Dougherty’s long history began in 1929 and continues today as one of Dallas’s oldest, largest and best-known full-service pharmacies, which also includes durable medical equipment, home healthcare products services, and health and wellness supplements. We have a customer service-oriented philosophy and typically do not attempt to compete solely based on price, as is the case with most of the national pharmacy chains.

Additional community pharmacies are located in Dallas, El Paso, and Springtown, Texas and in McAlester, Oklahoma.

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

RESULTS OF OPERATIONS

The following discussion explains the material changes in our results of operations for the nine months ended September 30, 2018 and 2017, and the significant developments affecting our financial condition since the Form 10-K filed March 29, 2018. We strongly recommend that you read our audited consolidated financial statements and notes thereto and Management’s Discussion and Analysis of Financial Condition and Results of Operations for the years ended December 31, 2017 and 2016 filed in that report, along with this report.

Comparison of the Three and Nine Months ended September 30, 2018, to the Three and Nine Months ended September 30, 2017 (000’s Omitted)

	Three Months ended September 30,						Nine Months Ended September 30,
	2018			2017			2018			2017

Revenue	$	8,761		$	9,947		$	27,384		$	30,213
Cost of sales		6,650			7,367			20,431			22,083
Gross profit		2,111			2,580			6,953			8,130
Operating expenses
Selling, General and Administrative		2,286			2,643			7,227			7,846
Depreciation and amortization		231			249			713			769
Other income		47			–			135			–
Interest income		–			–			33			–
Interest expense		(118	)		(115	)		(339	)		(317	)
Loss of disposal of assets		–			–			–			(75	)
Income tax provision		(2,006	)		(9	)		(2,022	)		(32	)
Net loss	$	(2,483	)	$	(436	)	$	(3,180	)	$	(909	)
plus:
Interest expense	$	118		$	115		$	339		$	317
Depreciation and amortization		231			249			713			769
Loss on disposal of assets		–			–			–			75
Income tax provision		2,006			9			2,022			32
EBITDA (Adjusted)	$	(128	)	$	(63	)	$	(106	)	$	284

Prescription count		98,115			107,178			303,923			328,399

Revenues

Net revenues decreased approximately $1,186,000 or 11.9%, and $2,829,000, or 9.4% in the three and nine months ended September 30, 2018. Retail pharmacy prescriptions sold decreased 9,000 or 8.5% and 24,000 or 7.5% for the three and nine months ended September 30, 2018. Net revenues and prescriptions for the nine months ended September 30, 2017 includes $177,000, and 2,313, respectively, from the Humble, Texas pharmacy, sold on May 6, 2017. Net revenues for the three and nine months ended September 30, 2018 includes $24,000,and $57,000, respectively, of front-end sales at the Legacy store, opened February 6, 2018 and also $27,000, and $75,000, respectively, of net retail pharmacy revenues and 949 and 2,212, retail pharmacy prescriptions, respectively. For the three and nine months ended September 30, 2018, pharmacy net revenues and prescriptions declined $923,000, and 10,000, respectively, and $2,559,000, and 24,000, respectively, after adjusting for the Humble, Texas and Legacy stores, primarily attributable to the transition of prescriptions filled for certain long-term care facilities and under certain third-party payor benefit plans that changed effective January 1, 2018, to other pharmacy providers. The initial focus of the Managing Director of Business Development appointed during the first quarter of 2018 has been to recoup these prescriptions.

Gross profit

Gross profit dollars decreased $469,000, or 18.2% and $1,177,000, or 14.5% in the three and nine months ended September 30, 2018, as compared to prior year. Gross profit as a percent of revenues decreased 180 basis points for the three months ended September 30, 2018, to 24.1% as compared to prior year. Gross profit as a percentage of net revenues decreased approximately 150 basis points in the nine months ended September 30, 2018 to 25.4%, as compared to prior year as a result of reduced reimbursement from certain third-party payor benefit plans that changed effective January 1, 2018, and continued increases in third party payor fees. Total third-party fees for the three and nine months September 30, 2018, ended increased $53,000, and $140,000, as compared to prior year. Net Direct and Indirect Remuneration fees during the three and nine months ended September 30, 2018, were comparable to the same quarter prior year.

SG&A expenses

SG&A expenses decreased $357,000, or 13.5% and $619,000, or 7.9% for the three and nine months ended September 30, 2018, as compared to prior year. SG&A expenses as a percentage of revenues for both the three months ended September 30, 2018, decreased to 26.1% as compared to 26.6% prior year. SG&A expenses as a percentage of revenues for both the three ended September 30, 2018, decreased to 26.4% as compared to 26.6% prior year, for the nine months ended September SG&A percentage of revenue increased to 26.3% from 26.0%. The decrease in SG&A expenses during the nine months ended September 30, 2018, is due to salary and payroll related cost savings from the resignations of the President of Pharmacy Operations and President and Chief Financial Officer during the fourth quarter of 2017 and first quarter of 2018, respectively, offset by the addition of the Managing Director of Business Development during the first quarter of 2018. Management plans to continue cost reduction initiatives during 2018 to decrease SG&A expenses as a percentage of revenues.

Earnings Before Interest, Taxes, Depreciation and Amortization

EBITDA decreased $65,000 and $390,000, respectively, for the three and nine months ended September 30, 2018, as compared to the same periods prior year. EBITDA as a percentage of revenues decreased 133 basis points for the nine months ended September 30, 2018, to -0.4% as compared to prior year. EBITDA as a percentage of net revenues decreased 133 basis points in the nine months ended September 30, 2018 to -0.4% as compared to prior year. The decrease in EBITDA basis points for the three and nine months ended September 30, 2018, compared to the same period during prior year, is a result of corresponding decreases in gross profit discussed above.

LIQUIDITY AND CAPITAL RESOURCES

As of September 30, 2018, we had working capital deficit of $3,720,000 as compared to working capital deficit of $1,954,000 million at December 31, 2017. The change in working capital is due to decreases in inventory and accounts payable. Note 6 in Item 1of the Financial Statements included in Part 1 of the Financial Information above.

As of September 30, 2018, we had cash of $206,000 as compared to $389,000, of which $303,000 was restricted, at December 31, 2017. The net decrease in cash for the nine months ended September 30, 2018, of $183,000 was due to the use of cash provided by operating activities for capital expenditures and financing activities discussed below.

As of September 30, 2018, the Company had total current assets of $4,940,000 and total current liabilities of $8,661,000 creating a working capital deficit of $3,720,000 as compared to total current assets of $6,242,000 and total current liabilities of $8,196,000 creating a working capital deficit of $1,954,000 at December 31, 2017. The overall decrease in working capital of $1,766,000 is primarily due to increased current portion of notes payable and decreases in cash, trade accounts receivable and inventory as a result of the decline in revenues discussed above.

The change in cash and cash equivalents is as follows:

	Nine Months Ended September 30,
	2018			2017

Net cash provided by operating activities	$	448		$	602
Net provided by (used in) investing activities		(121	)		877
Net cash used in financing activities		(510	)		(1,390	)
Net increase (decrease) increase in cash	$	(183	)	$	89

Net cash provided by operating activities was approximately $448,000 in the nine months ended September 30, 2018, compared to $602,000 in the nine months ended September 30, 2017. The decrease of $154,000 was primarily related to the decline in revenues discussed in “Revenues” above resulting in an increase in net loss of $252,000, increases cash provided from accounts receivable of $94,000, inventory of $708,000, prepaid expenses, other assets of $160,000 and accrued liabilities of $54,000 and increases in cash used by accounts payable of $227,000, accrued liabilities of $281 and net decreases in cash provided by other changes of $188,000.

Net cash (used in) provided by investing activities was approximately $(121,000) for the nine months ended September 30, 2018, compared to $877,000 provided by in the nine months ended September 30, 2017. Cash used to purchase property and equipment was $121,000 for the nine months ended September 30, 2018, compared to $85,000 for the prior year due to capital expenditures to open the new retail pharmacy location at The Campus at Legacy West in Plano, Texas, to expand long-term care facilities and for upgrades to the Preston Royal, Dallas, Texas location. For the nine months ended September 30, 2017, cash provided by the proceeds of the disposition of the Humble, Texas location was $274,000 and CPOC was $688,000.

Net cash used in financing activities was $510,000 in the nine months ended September 30, 2018, compared to cash used of $1,390,000 for the same period in 2017. For the nine months ended September 30, 2018, borrowings of $8,051,000 and payments of $7,926,000 were made on the revolving credit facility; payments of $634,000 were made on notes payable. For the nine months ended September 30, 2017, borrowings of $14,345,000 payments of $14,808,000 were made on the revolving credit facility; payments of $927,000 were made on notes payable. Certain proceeds from the disposition of CPOC were used to make certain payments on notes payable for the nine months ended September 30, 2017.

Our principal indebtedness at September 30, 2018, consists of the following:

	·	A number of term notes in favor of Cardinal Health in the aggregate amount of $2,979,000, secured by certain retail pharmacy assets, and maturing between August 2019 and August 2020;
	·	A revolving credit facility (the “Revolver”), which as of August 10, 2018, is in favor of OSK VII, LLC (the “Current Lender”) in the amount of $3,956,000 secured by certain retail pharmacy assets, and maturing between August 2019 and August 2020;

The material terms under these agreements include, without limitation, notice requirements for certain material events, the provision of periodic financial statements, the maintenance of certain financial ratios, maintaining certain minimum insurance requirements, as well as restrictions on our ability to incur additional indebtedness, incur future capital expenditures, as well as restrictions on our ability to purchase, create or acquire any interest in any other pharmacy store or distributing company, or loan, invest in or advance money or assets to any other person, enterprise or entity for the acquisition of a pharmacy store or distributing company without the prior written consent of the First National Bank of Omaha.

In addition, the Company was a co-guarantor on a promissory note issued by a bank in favor of an individual who was previously, through August of 2008, a related party of the Company. On April 3, 2018, total principal amount due and owing under the promissory note (the “Guarantee Payment”), was satisfied in full by the primary obligor. The restricted cash balance of $303,000, for which the Company was required to provide as escrow, was released as unrestricted and used for operations. In conjunction with the satisfaction of the of the obligation and release of restricted funds, the primary obligor paid the Company $33,000 interest for the 11 months ended September 30, 2018 during April of 2018 and $12,000 for the nine months ended September 31, 2017 during May of 2017.

On August 1, 2018, the Company was obligated to make payment of the outstanding principal of $3,956,000 plus $18,000 in accrued and unpaid interest under the Revolver with the First National Bank of Omaha (the “Lender”. Failure to make this payment on the August 1, 2018, maturity date was an event of default under the Revolver. The accrued interest of $18,000 was paid on August 2, 2018. An event of default under the Revolver permits the Lender, among other things, to foreclose on the assets securing the Revolver, which includes certain retail pharmacy assets, specifically but not limited to, inventory, equipment, software, accounts receivable, intangibles and deposit accounts of the Company (the “Secured Assets”). In addition to the failure to make the payment on the maturity date, as of August 1, 2018, the Company was not in compliance with its covenant to maintain a minimum debt service coverage ratio of not less than 1.00 to 1.00, as defined under the Revolver. Failure to maintain this financial covenant also constitutes an event of default under the Revolver.

On August 10, 2018, the Lender notified the Company that the Revolver had been sold to the Current Lender effective on August 10, 2018. This assignment of the Revolver from the Lender to the Current Lender does not affect any terms and condition of the Revolver and the associated loan documents. The Company does not currently have the ability to cure either events of default under the Revolver. Should the Current Lender elect to foreclose against the Secured Assets, it would significantly impair the Company's ability to continue as a going concern or to even be able to continue its operations. In light of these uncertainties, Management cannot provide any assurance that it can fund the Company’s capital needs in the near or long term. The Company is evaluating all of its options in light of these circumstances, including, without limitation, refinancing the indebtedness with another lender, negotiating a settlement arrangement with the Current Lender, or obtaining a temporary waiver or forbearance from the Current Lender; provided, however, the Company can provide no assurances that any of these arrangements can be entered into or if entered into would be upon terms and conditions beneficial to and acceptable by the Company. In light of these uncertainties, Management cannot provide any assurance that it can fund the Company’s capital needs in the near or long term.

Tax Loss Carryforwards

At December 31, 2017, we had approximately $48 million of federal net operating loss carryforwards available to offset future taxable income, which, if not utilized, will fully expire from 2020 to 2037. We believe that the issuance of shares of our common stock pursuant to our initial public offering on November 15, 1999 caused an “ownership change” for purposes of Section 382 of the Internal Revenue Code of 1986, as amended. Consequently, we believe that the portion of our federal NOL carryforwards attributable to the period prior to November 16, 1999 is subject to an annual limitation pursuant to Section 382. Our total deferred tax assets have been fully reserved as a result of the uncertainty of future taxable income. The estimated deferred tax asset as of September 30, 2018 has been fully reserved due to uncertainty of future income to utilize such asset.

Off Balance Sheet Arrangements

We do not have any unconsolidated special purpose entities and, except as described herein, we do not have significant exposure to any off-balance sheet arrangements. The term “off-balance sheet arrangement” generally means any transaction, agreement or other contractual arrangement to which an entity unconsolidated with us is a party, under which we have: (i) any obligation arising under a guarantee contract, derivative instrument or variable interest; or (ii) a retained or contingent interest in assets transferred to such entity or similar arrangement that serves as credit, liquidity or market risk support for such assets.

Critical Accounting Policies

We prepare our consolidated financial statements in conformity with GAAP, which requires management to make certain estimates and apply judgment. We base our estimates and judgments on historical experience, current trends and other factors that management believes to be important at the time the condensed consolidated financial statements are prepared. On a regular basis, we review our accounting policies and how they are applied and disclosed in our condensed consolidated financial statements.

While we believe that the historical experience, current trends and other factors considered support the preparation of our condensed consolidated financial statements in conformity with GAAP, actual results could differ from our estimates and such differences could be material.

For a full description of our significant accounting policies, please refer to the Notes to Consolidated Financial Statements in Item 1.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Our interim chief executive officer and interim chief financial officer evaluated the effectiveness of our disclosure controls and procedures (as defined in Rule 13a–15(e) under the Exchange Act) as of September 30, 2018. Based upon that evaluation, and in light of the Company’s delinquency in filing this quarterly report on Form 10-Q, our interim chief executive officer and interim chief financial officer concluded that as of September 30, 2018, our disclosure controls and procedures were not effective. We have taken the initial steps to remediate this failure in our disclosure controls by engaging an SEC compliance resource to assist in the preparation of our filing obligations. In addition to this, we are exploring the possibility of engaging a full-time Chief Financial Officer who would have responsibility for, among other things, overseeing the collection, dissemination, and processing of the information (financial and otherwise) required for us to meet our future disclosure obligations.

Changes in Internal Control over Financial Reporting

There were no changes in the Company’s internal control over financial reporting during the quarter ended September 30, 2018, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II – OTHER INFORMATION

Item 1. Legal Proceedings

From time to time, the Company may be subject to legal proceedings and claims in the ordinary course of business. We are not currently aware of any such proceedings or claims that we believe will have, individually or in the aggregate, a material adverse effect on our business, financial condition or results of operations.

Item 3. Defaults on Senior Securities.

Item 6. Exhibits

Exhibit Number		Description

10.1		Letter of Credit in the amount of $825,000 issued by Legacy Texas Bank for the benefit of Associated Food Stores Inc. (1)

31.1		Certification of the President - Chief Executive Officer pursuant to Rule 13a-14(a) of the Exchange Act (1)

31.2		Certification of the Chief Financial Officer pursuant to Rule 13a-14(a) of the Exchange Act (1)

32		Certification of the President - Chief Executive Officer and Chief Financial Officer pursuant to Rule 13a-14(b) of the Exchange Act and 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (1)

101.INS		XBRL Instances Document (1)
101.SCH		XBRL Taxonomy Extension Schema Document (1)
101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document (1)
101.DEF		XBRL Taxonomy Extension Definition Linkbase Document (1)
101.LAB		XBRL Taxonomy Extension Label Linkbase Document (1)
101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document (1)

(1)	Filed herewith.

SIGNATURES

Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the Company has duly caused this Quarterly Report on Form 10-Q to be signed on its behalf by the undersigned, thereunto duly authorized on April 29, 2019.

	DOUGHERTY’S PHARMACY, INC.


	By:	/s/ Stewart I. Edington
		Stewart I. Edington
		President and Chief Financial Officer

EXHIBIT INDEX

Exhibit Number		Description
		Letter of Credit in the amount of $825,000 issued by Legacy Texas Bank for the benefit of Associated Food Stores Inc. (1)
10.1

31.1		Certification of the President - Chief Executive Officer pursuant to Rule 13a-14(a) of the Exchange Act (1)

31.2		Certification of the Chief Financial Officer pursuant to Rule 13a-14(a) of the Exchange Act (1)

32		Certification of the President - Chief Executive Officer and Chief Financial Officer pursuant to Rule 13a-14(b) of the Exchange Act and 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (1)

101.INS		XBRL Instances Document (1)
101.SCH		XBRL Taxonomy Extension Schema Document (1)
101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document (1)
101.DEF		XBRL Taxonomy Extension Definition Linkbase Document (1)
101.LAB		XBRL Taxonomy Extension Label Linkbase Document (1)
101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document (1)

(1)	Filed herewith.

EX-10.1 2 dougherty_10q-ex1001.htm LETTER OF CREDIT

Exhibit 10.1

March 22, 2019

Travis Bowman, Controller
Associated Food Stores, Inc.
1850 West 2100 S.

Salt Lake City, UT 84119

Ladies and Gentlemen,

1. We hereby establish, at the request and for the account of Dougherty's Pharmacy, Inc., (the "Applicant") our Irrevocable Letter of Credit No. 444801 (the "Letter of Credit") in the initial amount of $825,000.00 (the "Letter of Credit Amount") effective as of the date referenced above, and expiring on March 22, 2020 (the "Expiration Date"). Notwithstanding the foregoing, this Letter of Credit shall be automatically renewed for additional periods of one year upon the Expiration Date and upon each anniversary of such date, unless at least sixty (60) days prior to the Expiration Date or anniversary thereof, as applicable, we notify you in writing that we elect not to renew his Letter of Credit for such additional period. Upon any such renewal, all references to the "Expiration Date" here in shall be deemed to refer to the Expiration Date as extended by such renewal. In the event that Lender elects to not renew the Letter of Credit, Beneficiary would be permitted to present the Letter of Credit for payment without the documentation required in Section 2 below. In addition, this letter of credit will be reduced by $100,000 at each anniversary of the Effective Date of this letter of credit (for the avoidance of doubt, as an example, during the second year after the Effective Date, the Letter of Credit may be at least $725,000.00 and in the third year, at least $625,000.00). Said decrease of this letter of credit shall be effective without any further action on the part of the Lender or notice to any party.

2. We irrevocably authorize you to draw upon us, in an aggregate amount not to exceed the Letter of Credit Amount, and in accordance with the terms and conditions set forth herein in multiple drawings by your draft in the form of Exhibit A hereto (the "Draft"), payable at sight on a Business Day, accompanied by a completed certificate in the form of Exhibit B hereto (the "Certificate") and the following documents (collectively the "Required Documents"):

Associated Food Stores, Inc. (AFS) is to present to the bank: A copy of the written notice sent by "Certified Mail" or delivered in person from AFS stating that Applicant is in default of its payment obligations for purchase of inventory.

AFS is to present to the bank: A notarized statement from AFS stating the following: "The Payment Default as per the prior written notice previously sent to Company remains uncured and remains in default after a 10 day period has passed from the date of the said written notice as previously presented and received by Company.

The Draft and Certificate must be in writing and signed by you. As used in this Letter of Credit, "Business Day" means any day other than a Saturday, Sunday or holiday on which LegacyTexas Bank is open for business with the public in Plano, Texas and "in writing" includes a transmission by telecopier.

P.O. Box 869105, Plano, TX 75086-9105 1972.578 5000 I 800.578.9009 I LegacyTexas.com
Member FDIC I C1' Equal Housing Lender I NMLS: 440732

3. Funds under this Letter of Credit are available to you against your Draft and Certificate. The Draft and Certificate are to bear the date of presentation, and are to be presented in person, with the original of this Letter of Credit, on or prior to the Expiration Date, to our Letter of Credit Department at 2101 Custer Road, Plano, TX 75075.

Upon receiving this Letter of Credit, the Required Documents, and your Draft and Certificate in strict conformity with the terms of this Letter of Credit on or prior to the Expiration Date and on or before 5:00 pm, Central Time, on a Business Day, on or prior to the time set forth in Paragraph 4 we either will honor the presentation through a credit to the account designated in your Draft or give written notice of discrepancies pursuant to Paragraph 4 which written notice shall include the return of the Letter of Credit.

4. If a presentation pursuant to Paragraph 3 does not conform to the terms and conditions of this Letter of Credit, we will notify you of discrepancies in writing by a notice of dishonor in substantially the form of Exhibit C hereto not later than 5:00 pm, Central Time, on the fifth (5`^h) Business Day following the Business Day of presentation. Prior to the Expiration Date, or within five (5) Business Days after receiving notice of dishonor, whichever is later, you may correct discrepancies and again present the Draft and other documents in accordance with Paragraph 3.

5. Only you may draw upon this Letter of Credit. After payment to the account designated by your Draft of the amount specified in your Draft, we will issue a new Letter of Credit under all of the same terms and conditions as contained herein in an amount equal to the remaining available balance which is the original Letter of Credit Amount set forth above less all payments made to date pursuant to the Letter of Credit and each replacement thereof. After payment to the account designated by your Draft of the full amount specified in this Letter of Credit, we shall be fully discharged from our obligations under this Letter of Credit. No person shall be deemed a third party beneficiary hereunder and no person other than Beneficiary may enforce a draw upon the Letter of Credit.

6. This Letter of Credit is governed by the laws of the State of Texas that are in force upon the date of this Letter of Credit. The Uniform Customs and Practices for Documentary Credits (2007 Revision), International Chamber of Commerce, Publication No. 600 (the "UCP"), governs this Letter of Credit to the extent permitted by the Texas enactment of Article 5 of the Uniform Commercial Code in force upon the date of this Letter of Credit. In the event of any conflict between the UCP and the Texas Uniform Commercial Code, the UCP shall control except as prohibited by the Texas Uniform Commercial Code.

7. This Letter of Credit sets forth our full and complete undertaking. This undertaking shall not in any way be modified, amended, amplified, or limited by the reference herein to any document, instrument, or agreement, (including, without limitation the Contract), except Exhibits A, B, C and D and consistent provisions of the UCP. This Letter of Credit may only be amended by an amendment signed by us and consented to in writing by you and the Applicant.

8. Any notice or demand required hereunder shall be in writing and deemed to be given when deposited in the United States mail, postage prepaid, certified mail, return receipt requested, addressed to the issuer or the beneficiary, as the case may be, at the address set forth herein, or at such other address as such party may hereafter give by written notice in accordance herewith. Any other method of delivery or demand shall be effective only when actually received by the recipient thereof. Notwithstanding the foregoing, draws on this Letter of Credit may only be submitted in person by an Officer of Beneficiary pursuant to Section 3.

9. We are not responsible for the performance or nonperformance of any underlying contract, arrangement or transaction, any act or omission of others, or the observance or knowledge of the usage of a particular trade other than the standard practice of financial institutions that regularly issue letters of credit. Notwithstanding anything contained in this Letter of Credit or related documents, we shall not be liable for consequential damages.

10. All charges and commissions of issuer incurred in this transaction are for the Applicant's account.

	Very truly yours,

	LEGACY TEXAS BANK

	By: /s/ Leah Smith

	Name: Leah Smith

	Title: Vice President

ADDRESSES FOR NOTICE

ISSUER:	BENEFICIARY:
LegacyTexas Bank	Travis Bowman, Controller
Attn: Leah Smith	Associated Food Stores, Inc.
2101 Custer Road	1850 West 2100 S.
Plano, TX 75075	Salt Lake City, UT 84119

EXHIBIT A

LETTER OF CREDIT No. 444801

FORM OF DRAFT

$__________

Plano, TX __________, 20

At sight pay to Account No. __________at_______, the sum of [*Amount In Words] ($[*Amount in Numbers*]). Drawn under the LegacyTexas Bank Irrevocable Letter of credit No. 444801 dated March 22, 2019. The amount of this draft does not exceed the amount available to be drawn by the undersigned beneficiary under the Letter of Credit.



	By: _______________________

	Name: _____________________

	Title: ______________________

To:	LEGACYTEXAS BANK
	Attn: Leah Smith
	2101 Custer Road
	Plano, TX 75075

EXHIBIT B

LETTER OF CREDIT No. 444801

FORM OF CERTIFICATE

The undersigned, a duly authorized officer of Associated Food Stores, Inc. ("Beneficiary"), hereby certifies to LegacyTexas Bank (the "Bank"), with reference to Irrevocable Letter of Credit No. 444801 (the "Letter of Credit") (the terms defined therein and not otherwise defined herein being used as therein defined), issued by the Bank in favor of Beneficiary, the following:

Attached hereto are the Required Documents as required by the Letter of Credit, which are originals or, if permitted by the Letter of Credit, true and correct copies thereof;

This certification is in conformity with the Letter of Credit;

Dougherty's Pharmacy, Inc. has defaulted in the payment of [*The Amount Requested Pursuant to the Draft Accompanying this Certificate*], which is due to Beneficiary pursuant to [*Describe Contract/Lease/Or other Document*].

Items described specifically in 2. A and B of the Original Letter of Credit.

IN WITNESS WHEREOF, Beneficiary has executed and delivered this certificate as of the day of _________, 20__.

	Associated Food Stores, Inc.

	By: _____________________

	Name: ____________________

	Title:_____________________

EXHIBIT C

LETTER OF CREDIT No. 444801

FORM OF NOTICE OF DISHONOR

Travis Bowman, Controller
Associated Food Stores, Inc.
1850 W. 2100 S.

Salt Lake City, UT 84119

Re:

Irrevocable Letter of Credit No. 444801

Ladies and Gentlemen:

You are hereby notified that we will not honor your demand for payment under the above- referenced Letter of Credit as evidenced by your Draft and Certificate dated __________, 20 which Draft and Certificate did not comply strictly with the terms and conditions of the Letter of Credit because:

We [use as applicable: herewith return/are holding at your disposal] your Draft, Certificate and the following Required Documents which were presented to us:

	1
	2
	3

	LEGACY TEXAS BANK

	By: __________________

	Name: Leah Smith

	Title: Vice President

EX-31.1 3 dougherty_10q-ex3101.htm CERTIFICATION CEO

EXHIBIT 31.1

CERTIFICATION

I, Stewart I. Edington President and Chief Executive Officer of Dougherty’s Pharmacy, Inc., certify that:

(1)

I have reviewed this quarterly report on Form 10-Q of Dougherty’s Pharmacy, Inc.;

(2)

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

(3)

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

(4)

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

(5)

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: April 29, 2019	/s/ Stewart I. Edington
	Stewart I. Edington
	President and Chief Executive Officer

EX-31.2 4 dougherty_10q-ex3102.htm CERTIFICATION CFO

EXHIBIT 31.2

CERTIFICATION

I, Stewart I. Edington, Interim Chief Financial Officer of Dougherty’s Pharmacy, Inc., certify that:

(1)

I have reviewed this quarterly report on Form 10-Q of Dougherty’s Pharmacy, Inc.;

(2)

(3)

(4)

(a)

(b)

(c)

(d)

(5)

(a)

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: April 29, 2019	/s/ Stewart I. Edington
	Stewart I. Edington
	Interim Chief Financial Officer

EX-32 5 dougherty_10q-ex32.htm CERTIFICATION PURSUANT TO RULE 13A-14(B) OF THE EXCHANGE ACT

EXHIBIT 32

CERTIFICATION PURSUANT TO RULE 13a-14(b) OF THE EXCHANGE ACT AND

18 U.S.C. SECTION 1350, AS ENACTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Dougherty’s Pharmacy, Inc. (the “Company”) on Form 10-Q, for the quarter ended September 30, 2018, (the “Report”) as filed with the Securities and Exchange Commission on the date hereof, each of the undersigned Officers of the Company does hereby certify, pursuant to 18 U.S.C. Section 1350, as enacted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1)	The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)); and

(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

April 29, 2019	/s/ Stewart I. Edington
	Stewart I. Edington
	President and Chief Executive Office
April 29, 2019	/s/ Stewart I. Edington
	Stewart I. Edington
	Interim Chief Financial Officer

The foregoing certification is being furnished solely pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and is not being filed as part of the Report or as a separate disclosure document.

GRAPHIC 6 ex1001_image1.jpg GRAPHIC begin 644 ex1001_image1.jpg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end EX-101.INS 7 mydp-20180930.xml XBRL INSTANCE FILE 0001080029 2018-01-01 2018-09-30 0001080029 2019-04-11 0001080029 2018-09-30 0001080029 2017-12-31 0001080029 2017-01-01 2017-09-30 0001080029 2016-12-31 0001080029 2017-09-30 0001080029 MYDP:DoughHoldingMember 2018-09-30 0001080029 MYDP:ASDSMember 2018-09-30 0001080029 us-gaap:RevolvingCreditFacilityMember 2018-09-30 0001080029 us-gaap:RevolvingCreditFacilityMember 2017-12-31 0001080029 MYDP:NotePayable2Member 2018-09-30 0001080029 MYDP:NotePayable2Member 2017-12-31 0001080029 MYDP:NotePayable3Member 2018-09-30 0001080029 MYDP:NotePayable3Member 2017-12-31 0001080029 MYDP:NotePayable4Member 2018-09-30 0001080029 MYDP:NotePayable4Member 2017-12-31 0001080029 MYDP:NotePayable5Member 2018-09-30 0001080029 MYDP:NotePayable5Member 2017-12-31 0001080029 MYDP:NotePayable6Member 2018-09-30 0001080029 MYDP:NotePayable6Member 2017-12-31 0001080029 MYDP:NotePayable7Member 2018-09-30 0001080029 MYDP:NotePayable7Member 2017-12-31 0001080029 MYDP:NotePayable8Member 2018-09-30 0001080029 MYDP:NotePayable8Member 2017-12-31 0001080029 MYDP:NotePayable2Member 2018-01-01 2018-09-30 0001080029 MYDP:NotePayable3Member 2018-01-01 2018-09-30 0001080029 MYDP:NotePayable4Member 2018-01-01 2018-09-30 0001080029 MYDP:NotePayable5Member 2018-01-01 2018-09-30 0001080029 MYDP:NotePayable6Member 2018-01-01 2018-09-30 0001080029 MYDP:NotePayable7Member 2018-01-01 2018-09-30 0001080029 MYDP:NotePayable8Member 2018-01-01 2018-09-30 0001080029 us-gaap:RestrictedStockUnitsRSUMember 2018-01-01 2018-09-30 0001080029 MYDP:RSU1Member 2018-01-01 2018-09-30 0001080029 MYDP:RSU2Member 2018-01-01 2018-09-30 0001080029 MYDP:RSU3Member 2018-01-01 2018-09-30 0001080029 MYDP:RSU4Member 2018-01-01 2018-09-30 0001080029 MYDP:RSU5Member 2018-01-01 2018-09-30 0001080029 MYDP:RSU1Member 2018-09-30 0001080029 MYDP:RSU2Member 2018-09-30 0001080029 MYDP:RSU3Member 2018-09-30 0001080029 MYDP:RSU4Member 2018-09-30 0001080029 MYDP:RSU5Member 2018-09-30 0001080029 MYDP:DirectorsMember 2018-01-01 2018-09-30 0001080029 MYDP:ChairmanMember 2018-01-01 2018-09-30 0001080029 MYDP:DoughHoldingMember 2018-01-01 2018-09-30 0001080029 MYDP:ASDSMember 2018-01-01 2018-09-30 0001080029 us-gaap:RevolvingCreditFacilityMember 2018-01-01 2018-09-30 0001080029 us-gaap:RevolvingCreditFacilityMember MYDP:FirstNationalBankMember 2018-01-01 2018-09-30 0001080029 us-gaap:RevolvingCreditFacilityMember MYDP:FirstNationalBankMember 2018-09-30 0001080029 MYDP:RSU6Member 2018-01-01 2018-09-30 0001080029 MYDP:RSU6Member 2018-09-30 0001080029 2018-07-01 2018-09-30 0001080029 2017-07-01 2017-09-30 0001080029 us-gaap:RestrictedStockUnitsRSUMember 2018-09-30 0001080029 MYDP:DirectorsMember 2018-07-01 2018-09-30 0001080029 MYDP:ChairmanMember 2018-07-01 2018-09-30 0001080029 MYDP:AssociatedFoodStoresMember 2019-03-22 0001080029 MYDP:HumbleTexasPhamacyMember 2017-01-01 2017-05-06 0001080029 MYDP:RevolverMember 2018-01-01 2018-09-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure Dougherty's Pharmacy, Inc. 0001080029 10-Q 2018-09-30 false --12-31 Yes Non-accelerated Filer Q3 2018 24127914

206000

86000

147000

303000

1585000

1673000

218000

345000

6000

2854000

3562000

77000

267000

4940000

6242000

472000

448000

956000

1045000

2389000

2892000

2000000

8757000

12627000

2896000

3123000

483000

429000

1326000

813000

8661000

8196000

1653000

2801000

10314000

10997000

2000

60214000

60221000

-61376000

-58196000

397000

-1557000

1630000

8757000

12627000

.0001

0.0001

7500000

0.0001

24112164

24003310

23082164

22973310

50000000

1.0

12000

116000

140000

658500

432859

1827850

1241350

744100

305350

Fixed rate of 8.11%

Prime plus 2.6%

Prime plus 2.38%

Prime plus 2.4%

5.5%

Rates vary up to 4.076%

LIBOR plus 3.25%

.0524

.0811

0.0785

0.0763

0.0765

.055

monthly

13641

15232

10344

6200

2545

2020-04-10

2020-07-10

2020-01-10

2020-08-10

2019-08-10

2018-09-30

929157

638850

378251

155220

4130000

1324000

1481000

2013 2014 2015 2016 2017 2018

1035100

120000

122100

150000

563000

80000

413450

115000

101850

85000

111600

481650

5000

20250

50000

406400

26000 31000 39000 0 114000 11000 221000

140000

658500

15000

45000

80000

140000

788000

806000

670000

674000

685000

3372000

6995000

33000

5000

90000

30000

3956000

3831000

1030000

true 2004-03-01 2010-09-01

Acquisition of retail pharmacy

Holding company for Investment in CRESA Partners of Orange County, L.P. ("CPOC")

6935000

7445000

3831000

242000

335000

1249000

1371000

786000

869000

521000

570000

181000

202000

97000

170000

5282000

4644000

1653000

2801000

Secured by, but not limited to, the accounts receivable, inventory and fixed assets

4000000

LIBOR plus 3.25%

0.0536

27384000

30213000

8761000

9947000

20431000

22083000

6650000

7367000

6953000

8130000

2111000

2580000

7233000

7820000

2285000

2632000

-6000

26000

1000

11000

713000

769000

231000

249000

7940000

8615000

2517000

2892000

-987000

-485000

-406000

-312000

135000

47000

33000

339000

317000

118000

115000

-75000

-1158000

-877000

-477000

-427000

2022000

32000

2006000

9000

-3180000

-909000

-2483000

-436000

-0.14

-0.04

-0.11

-0.02

23087347

22450017

23097914

22476821

6000

-197000

-94000

-708000

193000

-190000

-12000

-227000

388000

54000

334000

448000

602000

121000

85000

274000

688000

-121000

877000

8561000

15735000

8051000

14345000

-510000

-1390000

-183000

89000

206000

389000

361000

450000

24000

42000

336000

315000

1.       Organization and Significant Accounting Policies   Description of Business   Dougherty’s Pharmacy, Inc. (“Dougherty’s” or the “Company”) is a value-oriented company focused on successfully acquiring, managing and growing community-based pharmacies in the Southwest Region. Dougherty’s was incorporated in Delaware on August 8, 2000.   A summary of the Company’s investments at September 30, 2018, is shown in the table below:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="font-weight: bold">Date</td><td style="font-weight: bold"> </td> <td style="font-weight: bold">Entity</td><td style="font-weight: bold"> </td> <td style="font-weight: bold">Transaction Description</td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">% Ownership</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td> </td><td> </td> <td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: top; background-color: rgb(238,238,238); text-align: left"> <td style="width: 24%">March 2004</td><td style="width: 2%"> </td> <td style="width: 26%; text-align: left">Dougherty’s Holdings, Inc. and subsidiaries (“DHI”or “the Borrowers”)</td><td style="width: 2%"> </td> <td style="width: 30%; text-align: left">Acquisition of retail pharmacy</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: center"> </td><td style="width: 12%; text-align: center">100%</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td> </td><td> </td> <td> </td><td> </td> <td style="text-align: center"> </td><td style="text-align: center"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: top; background-color: rgb(238,238,238); text-align: left"> <td>September 2010</td><td> </td> <td style="text-align: left">ASDS of Orange County, Inc. (“ASDS”),</td><td> </td> <td style="text-align: left">Holding company for Investment in CRESA Partners of Orange County, L.P. (“CPOC”)</td><td> </td> <td style="text-align: center"> </td><td style="text-align: center">100%</td><td style="text-align: left"> </td></tr> </table>     On February 7, 2017, CRESA Partners of Orange County, L.P., an affiliate of Cresa Partners-West, Inc. was acquired by Savills Studley, Inc. liquidating the partnership interest in its entirety held by ASDS. ASDS remains active as a holding company for the remaining payouts.   On May 6, 2017, the Company sold its pharmacy in Humble, Texas, acquired in September 2014, and received total cash proceeds of $274,000 related to this transaction. The revenues and earnings of the pharmacy are not significant to the consolidated financial statements taken as a whole.   On February 6, 2018, the Company opened a new retail pharmacy location at The Campus at Legacy West in Plano, Texas (“Legacy”). This new location will offer pharmacy services and retail products to approximately 3,000 JCPenney Home Office employees and will be open to all other future tenants and visitors of The Campus at Legacy West. Dougherty’s is initially filling prescriptions via concierge service from its pharmacy on Campbell Road until Legacy completes its third-party contract enrollment process. The first year revenues for this location were less than $150,000. The location was closed on February 7, 2019.   Our business has historically required us to rely on cash flow from operations and upon borrowing under a $4,000,000 revolving credit facility (“the Revolver”) with the First National Bank of Omaha (the “Lender”) as our primary sources of funding to operate and meet our financial obligations. Historically, much of our debt, including the Revolver, has been renewed or refinanced in the ordinary course of business. However, on August 1, 2018, the Company was obligated to make payment of the outstanding principal of $3,956,000 plus $18,000 in accrued and unpaid interest under the Revolver. Failure to make this payment on the August 1, 2018, maturity date was an event of default under the Revolver. The accrued interest of $18,000 was paid on August 2, 2018. An event of default under the Revolver permits the Lender, among other things, to foreclose on the assets securing the Revolver, which includes certain retail pharmacy assets, specifically but not limited to, inventory, equipment, software, accounts receivable, intangibles and deposit accounts of the Company (the “Secured Assets”). In addition to the failure to make the payment on the maturity date, as of August 1, 2018, the Company was not in compliance with its covenant to maintain a minimum debt service coverage ratio of not less than 1.00 to 1.00, as defined under the Revolver. Failure to maintain this financial covenant also constitutes an event of default under the Revolver. In light of these uncertainties, Management cannot provide any assurance that it can fund the Company’s capital needs in the near or long term.   On August 10, 2018, the Lender notified the Company that the Revolver had been sold to OSK VII, LLC (the “Current Lender”) effective on August 10, 2018. This assignment of the Revolver from the Lender to the Current Lender does not affect any terms and condition of the Revolver and the associated loan documents. The Company does not currently have the ability to cure either events of default under the Revolver. Should the Current Lender elect to foreclose against the Secured Assets, it would significantly impair the Company's ability to continue as a going concern or to even be able to continue its operations. The Company is evaluating all of its options in light of these circumstances, including, without limitation, refinancing the indebtedness with another lender, negotiating a settlement arrangement with the Current Lender,  or obtaining a temporary waiver or forbearance from the Current Lender; provided, however, the Company can provide no assurances that any of these arrangements can be entered into or if entered into would be upon terms and conditions beneficial to and  acceptable by the Company. In light of these uncertainties, Management cannot provide any assurance that it can fund the Company’s capital needs in the near or long term.   We have historically maintained a level of liquidity sufficient to allow us to cover our cash needs in the short-term. Over the long-term, we have managed our cash and capital structure to maintain our financial position and maintain flexibility for future strategic initiatives. We continuously assess our working capital needs, debt and leverage levels, capital expenditure requirements, and future investments or acquisitions. As of September 30, 2018, we had cash of approximately $206,000, working capital deficit of $3,720,000 and total outstanding debt of $6,935,000. Cash provided from operating activities for the nine months ended September 30, 2018 was $448,000.   On March 22, 2019, the Company secured a letter of credit in the amount of $825,000 issued by Legacy Texas Bank for the benefit of Associated Food Stores, Inc. that renews annually with a reduction of $100,000 on each anniversary date.   Significant Accounting Policies   Basis of Presentation   The consolidated financial statements include the accounts of Dougherty’s and all subsidiaries for which the Company has a controlling financial interest. Dougherty’s uses the cost method of accounting to recognize investments in and income from entities where Dougherty’s does not have a significant influence. All intercompany balances and transactions have been eliminated in consolidation. The accompanying unaudited consolidated financial statements of the Company and its wholly owned subsidiaries have been prepared by the Company, in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and are presented in accordance with the requirements of Form 10-Q and Rule 10-01 of Regulation S-X and have not been audited. Accordingly, these unaudited consolidated financial statements do not include all of the information and notes required by GAAP for complete financial statements and should be read in conjunction with the audited consolidated financial statements and notes thereto for the fiscal year ended December 31, 2017 included in the Company’s Form 10-K. In the opinion of management, the interim unaudited consolidated financial statements included herein contain all adjustments, including normal recurring adjustments, considered necessary to present fairly the Company’s financial position, the results of operations and cash flows for the periods presented. Due to seasonality, the results of operations for the nine months ended September 30, 2018, are not necessarily indicative of the results to be expected for any future interim period for the year ending December 31, 2018.    Use of Estimates   The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.   Concentration of Credit Risk   The Company’s credit risk relates primarily to its trade accounts receivables and its receivables from affiliates, along with cash deposits maintained at financial institutions in excess of federally insured limits on interest bearing accounts. Management performs continuing evaluations of debtors’ financial condition and maintains an allowance for uncollectible accounts as determined necessary.   Accounts Receivable   Receivables recorded in the financial statements represent valid claims against debtors for services rendered or other charges arising on or before the balance sheet date. Management makes estimates of the collectability of accounts receivable. Specifically, management analyzes accounts receivable and historical bad debts, customer credit-worthiness, current economic trends, and changes in customer payment terms and collections trends when evaluating the adequacy of the allowance for doubtful accounts. Any change in the assumptions used in analyzing accounts receivable may result in additional allowances for doubtful accounts being recognized in the periods in which the change in assumptions occurs.   At September 30, 2018 and 2017, all of the trade accounts receivable were from retail pharmacy operations.   Inventories   Inventories consist of health care product finished goods held for resale, valued at the lower of cost using the first-in, first-out method or net realizable value. The Company maintains an estimated reserve against inventory for excess, slow-moving, and obsolete inventory as well as inventory for which carrying value is in excess of its net realizable value.    Long-Lived Assets   The Company evaluates the recoverability of the carrying value of its long-lived assets whenever events or circumstances indicate the carrying amount may not be recoverable. If a long-lived asset is tested for recoverability and the undiscounted estimated future cash flows expected to result from the use and eventual disposition of the asset is less than the carrying amount of the asset, the asset cost is adjusted to fair value and an impairment loss is recognized as the amount by which the carrying amount of a long-lived asset exceeds its fair value.    Revenue Recognition   Revenues generated by the retail pharmacy operations are reported at the estimated net realizable amounts expected to be received from individuals, third-party payors, institutional health care providers and others. The Company recognizes revenue from the sale of pharmaceutical products and retail merchandise as transactions occur and product is delivered to the customer. Revenue from product sales is recognized at the point of sale and service revenue is recognized at the time services are provided.    Sales and similar taxes collected from clients are excluded from revenues. The obligation is included in accounts payable until the taxes are remitted to the appropriate taxing authorities.   Substantially all revenues earned during the nine months ended September 30, 2018 and 2017, were earned from the retail pharmacy operations.   Cost of Sales   Cost of sales includes the purchase price of goods sold, prescription packaging, compounded prescription direct labor, inventory obsolescence, freight costs, cash discounts and vendor rebates. Rebates or refunds received by the Company from its suppliers are considered as an adjustment of the prices of the supplier’s products purchased by the Company.   Income Taxes   The Company accounts for income taxes in accordance with income tax accounting guidance (ASC 740, Income Taxes). The income tax accounting guidance results in two components of income tax expense: current and deferred. Current income tax expense reflects taxes to be paid or refunded for the current period by applying the provisions of the enacted tax law to the taxable income or excess of deductions over revenues. The Company determines deferred income taxes using the liability (or balance sheet) method. Under this method, the net deferred tax asset or liability is based on the tax effects of the differences between the book and tax bases of assets and liabilities, and enacted changes in tax rates and laws are recognized in the period in which they occur. Deferred income tax expense results from changes in deferred tax assets and liabilities between periods. Deferred tax assets are reduced by a valuation allowance if, based on the weight of evidence available, it is more-likely-than-not that some portion or all of a deferred tax asset will not be realized.   Tax positions are recognized if it is more-likely-than-not, based on the technical merits, that the tax position will be realized or sustained upon examination. The term more-likely-than-not means a likelihood of more than 50%; the terms examined and upon examination also include resolution of the related appeals or litigation processes, if any. A tax position that meets the more-likely-than-not recognition threshold is initially and subsequently measured as the largest amount of tax benefit that has a greater than 50% likelihood of being realized upon settlement with a taxing authority that has full knowledge of all relevant information. The determination of whether or not a tax position has met the more-likely-than-not recognition threshold considers the facts, circumstances and information available at the reporting date and is subject to management’s judgment.   On December 22, 2017, the President signed into law the “Tax Cuts and Jobs Act” (the “TCJA”). Among numerous changes to existing tax laws, the TCJA permanently reduces the federal corporate income tax rate from 35% to 21% effective January 1, 2018. The effects on deferred tax balances of changes in tax rates are required to be taken into consideration in the period in which the changes are enacted, regardless of when they are effective. As the result of the reduction of the corporate income tax rate under the TCJA, the Company estimated the revaluation of its net deferred tax assets and recorded a provisional noncash income tax loss of approximately $1.0 million for year ended December 31, 2017. As of September 30, 2018, the Company fully reserved its deferred tax asset resulting in a $2 million charge to the income statement due to uncertainty of future income to utilize such assets.    Earnings per Share   Basic earnings per share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted earnings per share is computed by dividing net loss and unrecognized stock-based compensation by the weighted-average number of common shares outstanding during the period and the unvested restricted stock units. The unrecognized stock-based compensation as of September 30, 2018 and 2017 is $12,000 and $116,000, respectively; the unvested restricted stock units are 140,000 and 658,500, respectively. Due to the net losses for both years, restricted stock units for 2018 and 2017 were anti-dilutive.   New Accounting Pronouncements   ASU No. 2016-02, Leases (Topic 842)   In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) ("ASU 2016-02"). ASU 2016-02 requires the lessee to recognize assets and liabilities for leases with lease terms of more than twelve months. For leases with a term of twelve months or less, the Company is permitted to make an accounting policy election by class of underlying asset not to recognize lease assets and lease liabilities. Further, the lease requires a finance lease to recognize both an interest expense and an amortization of the associated expense. Operating leases generally recognize the associated expense on a straight-line basis. ASU 2016-02 requires the Company to adopt the standard using a modified retrospective approach and becomes effective on January 1, 2019. The Company is currently evaluating the impact that ASU 2016-02 will have on its financial position, results of operations and cash flows. Our current minimum lease commitments are disclosed in Note 4.

Description of Business   Dougherty’s Pharmacy, Inc. (“Dougherty’s” or the “Company”) is a value-oriented company focused on successfully acquiring, managing and growing community-based pharmacies in the Southwest Region. Dougherty’s was incorporated in Delaware on August 8, 2000.   A summary of the Company’s investments at September 30, 2018, is shown in the table below:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="font-weight: bold">Date</td><td style="font-weight: bold"> </td> <td style="font-weight: bold">Entity</td><td style="font-weight: bold"> </td> <td style="font-weight: bold">Transaction Description</td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">% Ownership</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td> </td><td> </td> <td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: top; background-color: rgb(238,238,238); text-align: left"> <td style="width: 24%">March 2004</td><td style="width: 2%"> </td> <td style="width: 26%; text-align: left">Dougherty’s Holdings, Inc. and subsidiaries (“DHI”or “the Borrowers”)</td><td style="width: 2%"> </td> <td style="width: 30%; text-align: left">Acquisition of retail pharmacy</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: center"> </td><td style="width: 12%; text-align: center">100%</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td> </td><td> </td> <td> </td><td> </td> <td style="text-align: center"> </td><td style="text-align: center"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: top; background-color: rgb(238,238,238); text-align: left"> <td>September 2010</td><td> </td> <td style="text-align: left">ASDS of Orange County, Inc. (“ASDS”),</td><td> </td> <td style="text-align: left">Holding company for Investment in CRESA Partners of Orange County, L.P. (“CPOC”)</td><td> </td> <td style="text-align: center"> </td><td style="text-align: center">100%</td><td style="text-align: left"> </td></tr> </table>     On February 7, 2017, CRESA Partners of Orange County, L.P., an affiliate of Cresa Partners-West, Inc. was acquired by Savills Studley, Inc. liquidating the partnership interest in its entirety held by ASDS. ASDS remains active as a holding company for the remaining payouts.   On May 6, 2017, the Company sold its pharmacy in Humble, Texas, acquired in September 2014, and received total cash proceeds of $274,000 related to this transaction. The revenues and earnings of the pharmacy are not significant to the consolidated financial statements taken as a whole.   On February 6, 2018, the Company opened a new retail pharmacy location at The Campus at Legacy West in Plano, Texas (“Legacy”). This new location will offer pharmacy services and retail products to approximately 3,000 JCPenney Home Office employees and will be open to all other future tenants and visitors of The Campus at Legacy West. Dougherty’s is initially filling prescriptions via concierge service from its pharmacy on Campbell Road until Legacy completes its third-party contract enrollment process. The first year revenues for this location were less than $150,000. The location was closed on February 7, 2019.   Our business has historically required us to rely on cash flow from operations and upon borrowing under a $4,000,00 revolving credit facility (“the Revolver”) with the First National Bank of Omaha (the “Lender”) as our primary sources of funding to operate and meet our financial obligations. Historically, much of our debt, including the Revolver, has been renewed or refinanced in the ordinary course of business. However, on August 1, 2018, the Company was obligated to make payment of the outstanding principal of $3,956,000 plus $18,000 in accrued and unpaid interest under the Revolver. Failure to make this payment on the August 1, 2018, maturity date was an event of default under the Revolver. The accrued interest of $18,000 was paid on August 2, 2018. An event of default under the Revolver permits the Lender, among other things, to foreclose on the assets securing the Revolver, which includes certain retail pharmacy assets, specifically but not limited to, inventory, equipment, software, accounts receivable, intangibles and deposit accounts of the Company (the “Secured Assets”). In addition to the failure to make the payment on the maturity date, as of August 1, 2018, the Company was not in compliance with its covenant to maintain a minimum debt service coverage ratio of not less than 1.00 to 1.00, as defined under the Revolver. Failure to maintain this financial covenant also constitutes an event of default under the Revolver. . In light of these uncertainties, Management cannot provide any assurance that it can fund the Company’s capital needs in the near or long term.   On August 10, 2018, the Lender notified the Company that the Revolver had been sold to OSK VII, LLC (the “Current Lender”) effective on August 10, 2018. This assignment of the Revolver from the Lender to the Current Lender does not affect any terms and condition of the Revolver and the associated loan documents. The Company does not currently have the ability to cure either events of default under the Revolver. Should the Current Lender elect to foreclose against the Secured Assets, it would significantly impair the Company's ability to continue as a going concern or to even be able to continue its operations. The Company is evaluating all of its options in light of these circumstances, including, without limitation, refinancing the indebtedness with another lender, negotiating a settlement arrangement with the Current Lender,  or obtaining a temporary waiver or forbearance from the Current Lender; provided, however, the Company can provide no assurances that any of these arrangements can be entered into or if entered into would be upon terms and conditions beneficial to and  acceptable by the Company. In light of these uncertainties, Management cannot provide any assurance that it can fund the Company’s capital needs in the near or long term.   We have historically maintained a level of liquidity sufficient to allow us to cover our cash needs in the short-term. Over the long-term, we have managed our cash and capital structure to maintain our financial position and maintain flexibility for future strategic initiatives. We continuously assess our working capital needs, debt and leverage levels, capital expenditure requirements, and future investments or acquisitions. As of September 30, 2018, we had cash of approximately $206,000, working capital deficit of $3,720,000 and total outstanding debt of $6,935,000. Cash provided from operating activities for the nine months ended September 30, 2018 was $448,000.   On March 22, 2019, the Company secured a letter of credit in the amount of $825,000 issued by Legacy Texas Bank for the benefit of Associated Food Stores, Inc. that renews annually with a reduction of $100,000 on each anniversary date.

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="font-weight: bold">Date</td><td style="font-weight: bold"> </td> <td style="font-weight: bold">Entity</td><td style="font-weight: bold"> </td> <td style="font-weight: bold">Transaction Description</td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">% Ownership</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td> </td><td> </td> <td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: top; background-color: rgb(238,238,238); text-align: left"> <td style="width: 24%">March 2004</td><td style="width: 2%"> </td> <td style="width: 26%; text-align: left">Dougherty’s Holdings, Inc. and subsidiaries (“DHI”or “the Borrowers”)</td><td style="width: 2%"> </td> <td style="width: 30%; text-align: left">Acquisition of retail pharmacy</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: center"> </td><td style="width: 12%; text-align: center">100%</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td> </td><td> </td> <td> </td><td> </td> <td style="text-align: center"> </td><td style="text-align: center"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: top; background-color: rgb(238,238,238); text-align: left"> <td>September 2010</td><td> </td> <td style="text-align: left">ASDS of Orange County, Inc. (“ASDS”),</td><td> </td> <td style="text-align: left">Holding company for Investment in CRESA Partners of Orange County, L.P. (“CPOC”)</td><td> </td> <td style="text-align: center"> </td><td style="text-align: center">100%</td><td style="text-align: left"> </td></tr> </table>

Basis of Presentation   The consolidated financial statements include the accounts of Dougherty’s and all subsidiaries for which the Company has a controlling financial interest. Dougherty’s uses the cost method of accounting to recognize investments in and income from entities where Dougherty’s does not have a significant influence. All intercompany balances and transactions have been eliminated in consolidation. The accompanying unaudited consolidated financial statements of the Company and its wholly owned subsidiaries have been prepared by the Company, in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and are presented in accordance with the requirements of Form 10-Q and Rule 10-01 of Regulation S-X and have not been audited. Accordingly, these unaudited consolidated financial statements do not include all of the information and notes required by GAAP for complete financial statements and should be read in conjunction with the audited consolidated financial statements and notes thereto for the fiscal year ended December 31, 2017 included in the Company’s Form 10-K. In the opinion of management, the interim unaudited consolidated financial statements included herein contain all adjustments, including normal recurring adjustments, considered necessary to present fairly the Company’s financial position, the results of operations and cash flows for the periods presented. Due to seasonality, the results of operations for the nine months ended September 30, 2018, are not necessarily indicative of the results to be expected for any future interim period for the year ending December 31, 2018.

Use of Estimates   The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Concentration of Credit Risk   The Company’s credit risk relates primarily to its trade accounts receivables and its receivables from affiliates, along with cash deposits maintained at financial institutions in excess of federally insured limits on interest bearing accounts. Management performs continuing evaluations of debtors’ financial condition and maintains an allowance for uncollectible accounts as determined necessary.

Accounts Receivable   Receivables recorded in the financial statements represent valid claims against debtors for services rendered or other charges arising on or before the balance sheet date. Management makes estimates of the collectability of accounts receivable. Specifically, management analyzes accounts receivable and historical bad debts, customer credit-worthiness, current economic trends, and changes in customer payment terms and collections trends when evaluating the adequacy of the allowance for doubtful accounts. Any change in the assumptions used in analyzing accounts receivable may result in additional allowances for doubtful accounts being recognized in the periods in which the change in assumptions occurs.   At September 30, 2018 and 2017, all of the trade accounts receivable were from retail pharmacy operations.

Inventories   Inventories consist of health care product finished goods held for resale, valued at the lower of cost using the first-in, first-out method or net realizable value. The Company maintains an estimated reserve against inventory for excess, slow-moving, and obsolete inventory as well as inventory for which carrying value is in excess of its net realizable value.

Long-Lived Assets   The Company evaluates the recoverability of the carrying value of its long-lived assets whenever events or circumstances indicate the carrying amount may not be recoverable. If a long-lived asset is tested for recoverability and the undiscounted estimated future cash flows expected to result from the use and eventual disposition of the asset is less than the carrying amount of the asset, the asset cost is adjusted to fair value and an impairment loss is recognized as the amount by which the carrying amount of a long-lived asset exceeds its fair value.

Revenue Recognition   Revenues generated by the retail pharmacy operations are reported at the estimated net realizable amounts expected to be received from individuals, third-party payors, institutional health care providers and others. The Company recognizes revenue from the sale of pharmaceutical products and retail merchandise as transactions occur and product is delivered to the customer. Revenue from product sales is recognized at the point of sale and service revenue is recognized at the time services are provided.    Sales and similar taxes collected from clients are excluded from revenues. The obligation is included in accounts payable until the taxes are remitted to the appropriate taxing authorities.   Substantially all revenues earned during the nine months ended September 30, 2018 and 2017, were earned from the retail pharmacy operations.

Cost of Sales   Cost of sales includes the purchase price of goods sold, prescription packaging, compounded prescription direct labor, inventory obsolescence, freight costs, cash discounts and vendor rebates. Rebates or refunds received by the Company from its suppliers are considered as an adjustment of the prices of the supplier’s products purchased by the Company.

Income Taxes   The Company accounts for income taxes in accordance with income tax accounting guidance (ASC 740, Income Taxes). The income tax accounting guidance results in two components of income tax expense: current and deferred. Current income tax expense reflects taxes to be paid or refunded for the current period by applying the provisions of the enacted tax law to the taxable income or excess of deductions over revenues. The Company determines deferred income taxes using the liability (or balance sheet) method. Under this method, the net deferred tax asset or liability is based on the tax effects of the differences between the book and tax bases of assets and liabilities, and enacted changes in tax rates and laws are recognized in the period in which they occur. Deferred income tax expense results from changes in deferred tax assets and liabilities between periods. Deferred tax assets are reduced by a valuation allowance if, based on the weight of evidence available, it is more-likely-than-not that some portion or all of a deferred tax asset will not be realized.   Tax positions are recognized if it is more-likely-than-not, based on the technical merits, that the tax position will be realized or sustained upon examination. The term more-likely-than-not means a likelihood of more than 50%; the terms examined and upon examination also include resolution of the related appeals or litigation processes, if any. A tax position that meets the more-likely-than-not recognition threshold is initially and subsequently measured as the largest amount of tax benefit that has a greater than 50% likelihood of being realized upon settlement with a taxing authority that has full knowledge of all relevant information. The determination of whether or not a tax position has met the more-likely-than-not recognition threshold considers the facts, circumstances and information available at the reporting date and is subject to management’s judgment.   On December 22, 2017, the President signed into law the “Tax Cuts and Jobs Act” (the “TCJA”). Among numerous changes to existing tax laws, the TCJA permanently reduces the federal corporate income tax rate from 35% to 21% effective January 1, 2018. The effects on deferred tax balances of changes in tax rates are required to be taken into consideration in the period in which the changes are enacted, regardless of when they are effective. As the result of the reduction of the corporate income tax rate under the TCJA, the Company estimated the revaluation of its net deferred tax assets and recorded a provisional noncash income tax loss of approximately $1.0 million for year ended December 31, 2017. As of September 30, 2018, the Company fully reserved its deferred tax asset resulting in a $2 million charge to the income statement due to uncertainty of future income to utilize such assets.

Earnings per Share   Basic earnings per share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted earnings per share is computed by dividing net loss and unrecognized stock-based compensation by the weighted-average number of common shares outstanding during the period and the unvested restricted stock units. The unrecognized stock-based compensation as of September 30, 2018 and 2017 is $12,000 and $116,000, respectively; the unvested restricted stock units are 140,000 and 658,500, respectively. Due to the net losses for both years, restricted stock units for 2018 and 2017 were anti-dilutive.

New Accounting Pronouncements   ASU No. 2016-02, Leases (Topic 842)   In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) ("ASU 2016-02"). ASU 2016-02 requires the lessee to recognize assets and liabilities for leases with lease terms of more than twelve months. For leases with a term of twelve months or less, the Company is permitted to make an accounting policy election by class of underlying asset not to recognize lease assets and lease liabilities. Further, the lease requires a finance lease to recognize both an interest expense and an amortization of the associated expense. Operating leases generally recognize the associated expense on a straight-line basis. ASU 2016-02 requires the Company to adopt the standard using a modified retrospective approach and becomes effective on January 1, 2019. The Company is currently evaluating the impact that ASU 2016-02 will have on its financial position, results of operations and cash flows. Our current minimum lease commitments are disclosed in Note 4.

2.       Notes Payable   Notes payable consist of the following:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="padding-left: 10pt; text-indent: -10pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">September 30, 2018</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31, 2017</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center; padding-left: 10pt; text-indent: -10pt"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: center">(Unaudited)</td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: center">(Audited)</td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-indent: -10pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font-weight: bold; text-align: left; padding-left: 10pt; text-indent: -10pt">First National Bank of Omaha Credit Facility and Promissory Note secured by certain retail pharmacy assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 70%; text-align: left; padding-left: 10pt; text-indent: -10pt">Revolving line of credit in the principal amount of $4,000,000 and $4,450,000, interest at LIBOR plus 3.25% (5.24% at September 30, 2018)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">–</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">3,831,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-left: 10pt; text-indent: -10pt">Term note OSK VII, LLC principal amount of $3,956,000, interest at LIBOR plus 3.25% (5.36% at September 30, 2018)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,956,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt; text-indent: -10pt">Term note in the principal amount of $432,859 at fixed interest rate of 8.11% per annum payable in 36 monthly installments of $13,641. Final payment plus accrued and unpaid interest due in full on April 10, 2020.</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">242,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">335,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-left: 10pt; text-indent: -10pt">Term note in the principal amount of $1,827,850 with interest payable at prime plus 2.60% (7.85% at September 30, 2018) per annum payable in monthly installments of $15,232 plus interest, a final payment of $929,157 plus all accrued and unpaid interest due in full on July 10, 2020.</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,249,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,371,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt; text-indent: -10pt">Term note in the principal amount of $1,241,350 with interest payable at prime plus 2.60% (7.85% at September 30, 2018) per annum payable in monthly installments of $10,344 plus interest, a final payment of $638,850 plus all accrued and unpaid interest due in full on January 10, 2020.</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">786,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">869,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-left: 10pt; text-indent: -10pt">Term note in the principal amount of $744,100 with interest payable at prime plus 2.38% (7.63% at September 30, 2018) per annum payable in monthly installments of $6,200 plus interest, a final payment of $378,251 plus all accrued and unpaid interest due in full on August 10, 2020.</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">521,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">570,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt; text-indent: -10pt">Term note in the principal amount of $305,350 with interest payable at prime plus 2.40% (7.65% at September 30, 2018) per annum payable in monthly installments of $2,545 plus interest, a final payment of $155,220 plus all accrued and unpaid interest due in full on August 10, 2019.</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">181,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">202,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font-weight: bold; text-align: left; padding-left: 10pt; text-indent: -10pt">Acquisition Notes Payable, unsecured</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt; text-indent: -10pt">Notes payable to sellers of acquired pharmacies with varying monthly payments with interest at 5.5% due through September 2018.</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">97,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font-weight: bold; text-align: left; padding-left: 10pt; text-indent: -10pt">Insurance notes payable, secured by the respective insurance policies</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt; text-indent: -10pt">Notes payable for the Company’s insurance policy premiums with varying monthly payments due through September 2018. Interest rates vary up to 4.076%</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">170,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-left: 10pt; text-indent: -10pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,935,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,445,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 10pt; text-indent: -10pt">Less current portion</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(5,282,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(4,644,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 2.5pt; padding-left: 10pt; text-indent: -10pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,653,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,801,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   Future maturities of notes payable at September 30, 2018, are as follows:   <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 60%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 43%; text-align: left; vertical-align: middle">2018</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">4,130,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; vertical-align: middle">2019</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,324,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 1pt; vertical-align: middle">2020</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,481,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,935,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   The revolving credit facility (“the Revolver”) with the First National Bank of Omaha (“the Lender”) is secured by, but not limited to, the accounts receivable, inventory, and the fixed assets of the Borrowers. On July 1, 2017, the Company obtained an extension of the Revolver, through September 1, 2017. On August 9, 2017, the Company obtained an additional term for the Revolver in the amount of $4,450,000 effective September 1, 2017, and then effective February 1, 2018, in the amount of $4,000,000. Outstanding advances under the Revolver bore interest at LIBOR plus 3.25% (5.36% at September 30, 2018); accrued and unpaid interest on the Revolver was due monthly. All outstanding principal under the Revolver plus all accrued and unpaid interest thereon was due and payable in full on August 1, 2018 (See Note 6). On August 10, 2018, the Lender notified the Company that the Revolver had been sold to the Current Lender effective on August 10, 2018. This assignment of the Revolver from the Lender to the Current Lender does not affect any terms and condition of the Revolver and the associated loan documents. The Revolver is secured by certain retail pharmacy assets, specifically but not limited to, inventory, equipment, software, accounts receivable, intangibles and deposit accounts of the Company. The Revolver is subject to certain financial restrictions, now subject to the Current Lender’s prior written approval, including, but not limited to, capital expenditures not to exceed $200,000, additional indebtedness, acquisitions of entities and payment of dividends and distributions. Effective December 31, 2017, the Borrowers agreed to maintain a minimum debt service coverage ratio of not less than 1.00 to 1.00, as defined. As of September 30, 2018, the Borrowers were not in compliance with this financial covenant.

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="padding-left: 10pt; text-indent: -10pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">September 30, 2018</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31, 2017</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center; padding-left: 10pt; text-indent: -10pt"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: center">(Unaudited)</td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: center">(Audited)</td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-indent: -10pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font-weight: bold; text-align: left; padding-left: 10pt; text-indent: -10pt">First National Bank of Omaha Credit Facility and Promissory Note secured by certain retail pharmacy assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 70%; text-align: left; padding-left: 10pt; text-indent: -10pt">Revolving line of credit in the principal amount of $4,000,000 and $4,450,000, interest at LIBOR plus 3.25% (5.24% at September 30, 2018)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">–</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">3,831,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-left: 10pt; text-indent: -10pt">Term note OSK VII, LLC principal amount of $3,956,000, interest at LIBOR plus 3.25% (5.36% at September 30, 2018)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,956,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt; text-indent: -10pt">Term note in the principal amount of $432,859 at fixed interest rate of 8.11% per annum payable in 36 monthly installments of $13,641. Final payment plus accrued and unpaid interest due in full on April 10, 2020.</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">242,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">335,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-left: 10pt; text-indent: -10pt">Term note in the principal amount of $1,827,850 with interest payable at prime plus 2.60% (7.85% at September 30, 2018) per annum payable in monthly installments of $15,232 plus interest, a final payment of $929,157 plus all accrued and unpaid interest due in full on July 10, 2020.</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,249,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,371,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt; text-indent: -10pt">Term note in the principal amount of $1,241,350 with interest payable at prime plus 2.60% (7.85% at September 30, 2018) per annum payable in monthly installments of $10,344 plus interest, a final payment of $638,850 plus all accrued and unpaid interest due in full on January 10, 2020.</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">786,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">869,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-left: 10pt; text-indent: -10pt">Term note in the principal amount of $744,100 with interest payable at prime plus 2.38% (7.63% at September 30, 2018) per annum payable in monthly installments of $6,200 plus interest, a final payment of $378,251 plus all accrued and unpaid interest due in full on August 10, 2020.</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">521,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">570,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt; text-indent: -10pt">Term note in the principal amount of $305,350 with interest payable at prime plus 2.40% (7.65% at September 30, 2018) per annum payable in monthly installments of $2,545 plus interest, a final payment of $155,220 plus all accrued and unpaid interest due in full on August 10, 2019.</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">181,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">202,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font-weight: bold; text-align: left; padding-left: 10pt; text-indent: -10pt">Acquisition Notes Payable, unsecured</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt; text-indent: -10pt">Notes payable to sellers of acquired pharmacies with varying monthly payments with interest at 5.5% due through September 2018.</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">97,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font-weight: bold; text-align: left; padding-left: 10pt; text-indent: -10pt">Insurance notes payable, secured by the respective insurance policies</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt; text-indent: -10pt">Notes payable for the Company’s insurance policy premiums with varying monthly payments due through September 2018. Interest rates vary up to 4.076%</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">170,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-left: 10pt; text-indent: -10pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,935,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,445,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 10pt; text-indent: -10pt">Less current portion</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(5,282,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(4,644,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 2.5pt; padding-left: 10pt; text-indent: -10pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,653,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,801,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

3.       Stock and Share-Based Compensation   Restricted Share Unit Incentive Plan   On November 13, 2013, the Board of Directors approved and adopted the Restricted Share Unit (“RSU”) Incentive Plan. Under the plan the Company can award RSUs to employees and non-employee directors and consultants pursuant to restricted stock agreements contingent upon continuous service. Under the restricted stock agreements, the restricted shares will vest annually over a four-year period and will be payable in stock, valued at the fair market value on the grant date.   As of September 30, 2018, the following shares had been issued under the 2013 RSU Plan:   <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year of Issuance:</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of Shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Fair Value at Date of Grant</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Shares Vested</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Non-Vested</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Cancelled</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 10%; text-align: center">2013</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">120,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">26,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">115,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">–</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">5,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center">2014</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">122,100</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">31,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">101,850</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">20,250</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: center">2015</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">150,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">39,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">85,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">15,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">50,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center">2016</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: center">2017</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">563,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">114,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">111,600</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">45,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">406,400</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center; padding-bottom: 1pt">2018</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">80,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">11,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">80,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">–</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: center; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">1,035,100</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">221,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">413,450</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">140,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">481,650</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr></table>

<table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year of Issuance:</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of Shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Fair Value at Date of Grant</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Shares Vested</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Non-Vested</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Cancelled</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 10%; text-align: center">2013</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">120,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">26,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">115,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">–</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">5,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center">2014</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">122,100</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">31,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">101,850</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">20,250</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: center">2015</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">150,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">39,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">85,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">15,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">50,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center">2016</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">–</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: center">2017</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">563,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">114,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">111,600</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">45,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">406,400</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center; padding-bottom: 1pt">2018</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">80,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">11,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">80,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">–</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: center; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">1,035,100</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">221,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">413,450</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">140,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">481,650</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr></table>

4.       Commitments and Contingencies   Operating Leases   The Company leases their pharmacy, corporate offices and certain pharmacy equipment under non-cancelable operating lease agreements. Certain leases contain renewal options and provide that the Company pay taxes, insurance, maintenance and other operating expenses.   Minimum lease payments under all non-cancelable operating lease agreements for the nine months ended September 30, 2018, are as follows:   <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 60%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 43%; text-align: left; vertical-align: middle">2018</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">788,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; vertical-align: middle">2019</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">806,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; vertical-align: middle">2020</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">670,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; vertical-align: middle">2021</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">674,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; vertical-align: middle">2022</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">685,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Thereafter</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">3,372,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,995,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   Legal Proceedings   The Company is occasionally involved in other claims and proceedings, which are incidental to its business. It is the opinion of management that the disposition or ultimate resolution of such claims and lawsuits will not have a material adverse effect on the consolidated financial position, results of operations and cash flows of the Company.

<table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 60%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 43%; text-align: left; vertical-align: middle">2018</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">788,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; vertical-align: middle">2019</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">806,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; vertical-align: middle">2020</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">670,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; vertical-align: middle">2021</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">674,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; vertical-align: middle">2022</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">685,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Thereafter</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">3,372,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">6,995,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

5.       Related Party Transactions   During the three and nine months ended September 30, 2018, the Company paid fees to its directors of $5,000 and $33,000 for their roles as members of the Board of Directors and its related committees; fees paid to the Company’s Chairman totaled $30,000 and $90,000 for management and other services provided.

6.       Subsequent Events   On March 22, 2019, the Company secured a letter of credit in the amount of $825,000 issued by Legacy Texas Bank for the benefit of Associated Food Stores, Inc. that renews annually with a reduction of $100,000 on each anniversary date.   The Legacy West Campus in Plano, Texas was closed on February 4, 2019.

825000

2000000

18000

-3720000

3956000

false false EX-101.SCH 8 mydp-20180930.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Consolidated Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Consolidated Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Disclosure - Reconciliation of Cash to the Consolidated Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - 1. Organization and Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - 2. Notes Payable link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - 3. Stock and Share-Based Compensation link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - 4. Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - 5. Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - 6. Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - 1. Organization and Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - 1. Organization and Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - 2. Notes Payable (Tables) link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - 3. Stock and Share-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - 4. Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - 1. Organization and Significant Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - 1. Organization and Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - 2. Notes Payable (Details - Notes payable) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - 2. Notes Payable (Details - Future debt maturities) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - 2. Notes Payable (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - 3. Stock and Share-Based Compensation (Details) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - 4. Commitments and Contingencies (Details - Minimum lease payments) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - 5. Related Party Transactions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 9 mydp-20180930_cal.xml XBRL CALCULATION FILE EX-101.DEF 10 mydp-20180930_def.xml XBRL DEFINITION FILE EX-101.LAB 11 mydp-20180930_lab.xml XBRL LABEL FILE Legal Entity [Axis] Dougherty's Holdings, Inc. [Member] ASDS of Orange County, Inc. [Member] Long-term Debt, Type [Axis] Revolving Credit Facility [Member] Term Note 1 [Member] Term Note 2 [Member] Term Note 3 [Member] Term Note 4 [Member] Term Note 5 [Member] Acquisition Notes Payable [Member] Insurance Notes Payable [Member] Award Type [Axis] Restricted Stock Units (RSUs) [Member] RSU 1 [Member] RSU 2 [Member] RSU 3 [Member] RSU 4 [Member] RSU 5 [Member] Related Party [Axis] Directors [Member] Chairman [Member] Credit Facility [Axis] Lender Name [Axis] First National Bank [Member] RSU 6 [Member] Counterparty Name [Axis] Associated Food Stores [Member] Disposal Group Classification [Axis] Humble Texas Pharmacy [Member] Revolver [Member] Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Is Entity a Well-known Seasoned Issuer? Is Entity a Voluntary Filer? Is Entity's Reporting Status Current? Entity Filer Category Entity Public Float Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus Entity Small Business Entity Emerging Growth Entity Transition Statement of Financial Position [Abstract] ASSETS Current Assets Cash Restricted cash Trade accounts receivable, net Other receivables Receivable from affiliates Inventories, net Prepaid expenses Total current assets Long term receivable Property and equipment, net Intangible assets, net Deferred tax asset Total assets LIABILITIES Current Liabilities Accounts payable Accrued liabilities Notes payable, current portion Revolving credit facility Total current liabilities Notes payable, long-term portion Total liabilities Stockholders' equity: Preferred stock, $0.0001 par value; 7,500,000 shares authorized: none issued and outstanding Common stock, $0.0001 par value; 50,000,000 shares authorized; 24,112,164 shares issued and 23,082,164 shares outstanding at September 30, 2018; 24,003,310 shares issued and 22,973,310 shares outstanding at December 31, 2017 Additional paid-in capital Accumulated deficit Treasury stock, at cost, 1,030,000 shares Total stockholders' equity Total liabilities and stockholders' equity Preferred stock, par value Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Treasury stock, at cost Income Statement [Abstract] Revenue Cost of sales (exclusive of depreciation and amortization shown separately down below) Gross profit Operating expenses Selling, general and administrative expenses Non-cash stock compensation Depreciation and amortization Total operating expenses Operating loss Other income Interest income Interest expense Loss on disposal of assets and investment impairment Loss before provision for income tax Income tax provision Net loss Basic and diluted net loss per share attributable to common stockholders Weighted-average number of shares - Basic and diluted Statement of Cash Flows [Abstract] Operating Activities Net loss Items not requiring (providing) cash Loss from disposal of assets Provision for doubtful accounts Change in deferred tax asset Stock-based compensation Changes in operating assets and liabilities: Accounts receivable Inventories Prepaid expenses and other assets Accounts payable Accrued liabilities Net cash provided by operating activities Investing Activities Purchases of property and equipment Cash received upon disposition of pharmacy Cash received upon disposition of CPOC Net (used in) provided by investing activities Financing Activities Payments on notes payable Proceeds from notes payable Net cash used in financing activities Net (decrease) increase in cash Cash, beginning of period Cash, end of period Supplemental Cash Flow Information Cash paid for income taxes Cash paid for interest Total cash and restricted cash Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization and Significant Accounting Policies Debt Disclosure [Abstract] Notes Payable Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Stock and Share-Based Compensation Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Related Party Transactions [Abstract] Related Party Transactions Subsequent Events [Abstract] Subsequent Events Description of Business Basis of Presentation Use of Estimates Reclassification Concentration of Credit Risk Accounts Receivable Inventories Long-Lived Assets Revenue Recognition Cost of Sales Income Taxes Earnings per Share New Accounting Pronouncements Schedule of Investments Schedule of notes payable Future maturities of notes payable Restricted stock activity Schedule of minimum operating lease payments Statement [Table] Statement [Line Items] Ownership percentage Date of investment Transaction description Interest expense Credit line amount outstanding Cash and restricted cash Working capital Total debt outstanding Cash provided from operating activities Letter of credit Unrecognized stock based compensation Unvested restricted stock units Antidilutive shares excluded from EPS Notes payable Notes payable - current Notes payable - long term Debt face amount Interest rate description Interest rate at period end Debt maturity date Debt periodic frequency Debt periodic payment EX-101.PRE 12 mydp-20180930_pre.xml XBRL PRESENTATION FILE XML 13 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2018	Apr. 11, 2019
Document And Entity Information
Entity Registrant Name	Dougherty's Pharmacy, Inc.
Entity Central Index Key	0001080029
Document Type	10-Q
Document Period End Date	Sep. 30, 2018
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding		24,127,914
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2018
Entity Small Business	true
Entity Emerging Growth	false
Entity Transition	false

XML 14 R2.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Current Assets
Cash	$ 206	$ 86
Restricted cash	0	303
Trade accounts receivable, net	1,585	1,673
Other receivables	218	345
Receivable from affiliates	0	6
Inventories, net	2,854	3,562
Prepaid expenses	77	267
Total current assets	4,940	6,242
Long term receivable	472	448
Property and equipment, net	956	1,045
Intangible assets, net	2,389	2,892
Deferred tax asset	0	2,000
Total assets	8,757	12,627
Current Liabilities
Accounts payable	2,896	3,123
Accrued liabilities	483	429
Notes payable, current portion	1,326	813
Revolving credit facility	3,956	3,831
Total current liabilities	8,661	8,196
Notes payable, long-term portion	1,653	2,801
Total liabilities	10,314	10,997
Stockholders' equity:
Preferred stock, $0.0001 par value; 7,500,000 shares authorized: none issued and outstanding	0	0
Common stock, $0.0001 par value; 50,000,000 shares authorized; 24,112,164 shares issued and 23,082,164 shares outstanding at September 30, 2018; 24,003,310 shares issued and 22,973,310 shares outstanding at December 31, 2017	2	2
Additional paid-in capital	60,214	60,221
Accumulated deficit	(61,376)	(58,196)
Treasury stock, at cost, 1,030,000 shares	(397)	(397)
Total stockholders' equity	(1,557)	1,630
Total liabilities and stockholders' equity	$ 8,757	$ 12,627

XML 15 R3.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2018	Dec. 31, 2017
Statement of Financial Position [Abstract]
Preferred stock, par value	$ .0001	$ 0.0001
Preferred stock, shares authorized	7,500,000	7,500,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	50,000,000	50,000,000
Common stock, shares issued	24,112,164	24,003,310
Common stock, shares outstanding	23,082,164	22,973,310
Treasury stock, at cost	1,030,000	1,030,000

XML 16 R4.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Income Statement [Abstract]
Revenue	$ 8,761	$ 9,947	$ 27,384	$ 30,213
Cost of sales (exclusive of depreciation and amortization shown separately down below)	6,650	7,367	20,431	22,083
Gross profit	2,111	2,580	6,953	8,130
Operating expenses
Selling, general and administrative expenses	2,285	2,632	7,233	7,820
Non-cash stock compensation	1	11	(6)	26
Depreciation and amortization	231	249	713	769
Total operating expenses	2,517	2,892	7,940	8,615
Operating loss	(406)	(312)	(987)	(485)
Other income	47	0	135	0
Interest income	0	0	33	0
Interest expense	(118)	(115)	(339)	(317)
Loss on disposal of assets and investment impairment	0	0	0	(75)
Loss before provision for income tax	(477)	(427)	(1,158)	(877)
Income tax provision	(2,006)	(9)	(2,022)	(32)
Net loss	$ (2,483)	$ (436)	$ (3,180)	$ (909)
Basic and diluted net loss per share attributable to common stockholders	$ (0.11)	$ (0.02)	$ (0.14)	$ (0.04)
Weighted-average number of shares - Basic and diluted	23,097,914	22,476,821	23,087,347	22,450,017

XML 17 R5.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Operating Activities
Net loss	$ (3,180)	$ (909)
Items not requiring (providing) cash
Loss from disposal of assets	0	75
Provision for doubtful accounts	0	6
Depreciation and amortization	713	769
Change in deferred tax asset	2,000	0
Stock-based compensation	(6)	26
Changes in operating assets and liabilities:
Accounts receivable	197	94
Inventories	708	(193)
Prepaid expenses and other assets	190	12
Accounts payable	(227)	388
Accrued liabilities	54	334
Net cash provided by operating activities	448	602
Investing Activities
Purchases of property and equipment	(121)	(85)
Cash received upon disposition of pharmacy	0	274
Cash received upon disposition of CPOC	0	688
Net (used in) provided by investing activities	(121)	877
Financing Activities
Payments on notes payable	(8,561)	(15,735)
Proceeds from notes payable	8,051	14,345
Net cash used in financing activities	(510)	(1,390)
Net (decrease) increase in cash	(183)	89
Cash, beginning of period	389	361
Cash, end of period	206	450
Supplemental Cash Flow Information
Cash paid for income taxes	24	42
Cash paid for interest	$ 336	$ 315

XML 18 R6.htm IDEA: XBRL DOCUMENT

Reconciliation of Cash to the Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017	Sep. 30, 2017	Dec. 31, 2016
Statement of Cash Flows [Abstract]
Cash	$ 206	$ 86	$ 147
Restricted cash	0	303	303
Total cash and restricted cash	$ 206	$ 389	$ 450	$ 361

XML 19 R7.htm IDEA: XBRL DOCUMENT

1. Organization and Significant Accounting Policies

9 Months Ended

Sep. 30, 2018

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Organization and Significant Accounting Policies

1. Organization and Significant Accounting Policies

Description of Business

A summary of the Company’s investments at September 30, 2018, is shown in the table below:

Date	Entity	Transaction Description	% Ownership

March 2004	Dougherty’s Holdings, Inc. and subsidiaries (“DHI”or “the Borrowers”)	Acquisition of retail pharmacy		100%

September 2010	ASDS of Orange County, Inc. (“ASDS”),	Holding company for Investment in CRESA Partners of Orange County, L.P. (“CPOC”)		100%

Significant Accounting Policies

Basis of Presentation

Use of Estimates

Concentration of Credit Risk

Accounts Receivable

At September 30, 2018 and 2017, all of the trade accounts receivable were from retail pharmacy operations.

Inventories

Long-Lived Assets

Revenue Recognition

Sales and similar taxes collected from clients are excluded from revenues. The obligation is included in accounts payable until the taxes are remitted to the appropriate taxing authorities.

Substantially all revenues earned during the nine months ended September 30, 2018 and 2017, were earned from the retail pharmacy operations.

Cost of Sales

Income Taxes

Earnings per Share

New Accounting Pronouncements

ASU No. 2016-02, Leases (Topic 842)

XML 20 R8.htm IDEA: XBRL DOCUMENT

2. Notes Payable

9 Months Ended

Sep. 30, 2018

Debt Disclosure [Abstract]

Notes Payable

2. Notes Payable

Notes payable consist of the following:

	September 30, 2018			December 31, 2017
		(Unaudited)			(Audited)

First National Bank of Omaha Credit Facility and Promissory Note secured by certain retail pharmacy assets
Revolving line of credit in the principal amount of $4,000,000 and $4,450,000, interest at LIBOR plus 3.25% (5.24% at September 30, 2018)	$	–		$	3,831,000
Term note OSK VII, LLC principal amount of $3,956,000, interest at LIBOR plus 3.25% (5.36% at September 30, 2018)		3,956,000
Term note in the principal amount of $432,859 at fixed interest rate of 8.11% per annum payable in 36 monthly installments of $13,641. Final payment plus accrued and unpaid interest due in full on April 10, 2020.		242,000			335,000
Term note in the principal amount of $1,827,850 with interest payable at prime plus 2.60% (7.85% at September 30, 2018) per annum payable in monthly installments of $15,232 plus interest, a final payment of $929,157 plus all accrued and unpaid interest due in full on July 10, 2020.		1,249,000			1,371,000
Term note in the principal amount of $1,241,350 with interest payable at prime plus 2.60% (7.85% at September 30, 2018) per annum payable in monthly installments of $10,344 plus interest, a final payment of $638,850 plus all accrued and unpaid interest due in full on January 10, 2020.		786,000			869,000
Term note in the principal amount of $744,100 with interest payable at prime plus 2.38% (7.63% at September 30, 2018) per annum payable in monthly installments of $6,200 plus interest, a final payment of $378,251 plus all accrued and unpaid interest due in full on August 10, 2020.		521,000			570,000
Term note in the principal amount of $305,350 with interest payable at prime plus 2.40% (7.65% at September 30, 2018) per annum payable in monthly installments of $2,545 plus interest, a final payment of $155,220 plus all accrued and unpaid interest due in full on August 10, 2019.		181,000			202,000
Acquisition Notes Payable, unsecured
Notes payable to sellers of acquired pharmacies with varying monthly payments with interest at 5.5% due through September 2018.		–			97,000
Insurance notes payable, secured by the respective insurance policies
Notes payable for the Company’s insurance policy premiums with varying monthly payments due through September 2018. Interest rates vary up to 4.076%		–			170,000
		6,935,000			7,445,000
Less current portion		(5,282,000	)		(4,644,000	)
	$	1,653,000		$	2,801,000

Future maturities of notes payable at September 30, 2018, are as follows:

2018	$	4,130,000
2019		1,324,000
2020		1,481,000
	$	6,935,000

XML 21 R9.htm IDEA: XBRL DOCUMENT

3. Stock and Share-Based Compensation

9 Months Ended

Sep. 30, 2018

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Stock and Share-Based Compensation

3. Stock and Share-Based Compensation

Restricted Share Unit Incentive Plan

As of September 30, 2018, the following shares had been issued under the 2013 RSU Plan:

Year of Issuance:	Number of Shares		Fair Value at Date of Grant		Shares Vested		Non-Vested		Cancelled
2013		120,000	$	26,000		115,000		–		5,000
2014		122,100	$	31,000		101,850		–		20,250
2015		150,000	$	39,000		85,000		15,000		50,000
2016		–		–		–		–		–
2017		563,000	$	114,000		111,600		45,000		406,400
2018		80,000	$	11,000		–		80,000		–
		1,035,100	$	221,000		413,450		140,000		481,650

XML 22 R10.htm IDEA: XBRL DOCUMENT

4. Commitments and Contingencies

9 Months Ended

Sep. 30, 2018

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

4. Commitments and Contingencies

Operating Leases

Minimum lease payments under all non-cancelable operating lease agreements for the nine months ended September 30, 2018, are as follows:

2018	$	788,000
2019		806,000
2020		670,000
2021		674,000
2022		685,000
Thereafter		3,372,000
	$	6,995,000

Legal Proceedings

XML 23 R11.htm IDEA: XBRL DOCUMENT

5. Related Party Transactions

9 Months Ended

Sep. 30, 2018

Related Party Transactions

5. Related Party Transactions

XML 24 R12.htm IDEA: XBRL DOCUMENT

6. Subsequent Events

9 Months Ended

Sep. 30, 2018

Subsequent Events [Abstract]

Subsequent Events

6. Subsequent Events

The Legacy West Campus in Plano, Texas was closed on February 4, 2019.

XML 25 R13.htm IDEA: XBRL DOCUMENT

1. Organization and Significant Accounting Policies (Policies)

9 Months Ended

Sep. 30, 2018

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Description of Business

Description of Business

A summary of the Company’s investments at September 30, 2018, is shown in the table below:

Date	Entity	Transaction Description	% Ownership

March 2004	Dougherty’s Holdings, Inc. and subsidiaries (“DHI”or “the Borrowers”)	Acquisition of retail pharmacy		100%

September 2010	ASDS of Orange County, Inc. (“ASDS”),	Holding company for Investment in CRESA Partners of Orange County, L.P. (“CPOC”)		100%

Our business has historically required us to rely on cash flow from operations and upon borrowing under a $4,000,00 revolving credit facility (“the Revolver”) with the First National Bank of Omaha (the “Lender”) as our primary sources of funding to operate and meet our financial obligations. Historically, much of our debt, including the Revolver, has been renewed or refinanced in the ordinary course of business. However, on August 1, 2018, the Company was obligated to make payment of the outstanding principal of $3,956,000 plus $18,000 in accrued and unpaid interest under the Revolver. Failure to make this payment on the August 1, 2018, maturity date was an event of default under the Revolver. The accrued interest of $18,000 was paid on August 2, 2018. An event of default under the Revolver permits the Lender, among other things, to foreclose on the assets securing the Revolver, which includes certain retail pharmacy assets, specifically but not limited to, inventory, equipment, software, accounts receivable, intangibles and deposit accounts of the Company (the “Secured Assets”). In addition to the failure to make the payment on the maturity date, as of August 1, 2018, the Company was not in compliance with its covenant to maintain a minimum debt service coverage ratio of not less than 1.00 to 1.00, as defined under the Revolver. Failure to maintain this financial covenant also constitutes an event of default under the Revolver. . In light of these uncertainties, Management cannot provide any assurance that it can fund the Company’s capital needs in the near or long term.

Basis of Presentation

Basis of Presentation

Use of Estimates

Use of Estimates

Concentration of Credit Risk

Concentration of Credit Risk

Accounts Receivable

Accounts Receivable

At September 30, 2018 and 2017, all of the trade accounts receivable were from retail pharmacy operations.

Inventories

Inventories

Long-Lived Assets

Long-Lived Assets

Revenue Recognition

Revenue Recognition

Sales and similar taxes collected from clients are excluded from revenues. The obligation is included in accounts payable until the taxes are remitted to the appropriate taxing authorities.

Substantially all revenues earned during the nine months ended September 30, 2018 and 2017, were earned from the retail pharmacy operations.

Cost of Sales

Cost of Sales

Income Taxes

Income Taxes

Earnings per Share

Earnings per Share

New Accounting Pronouncements

New Accounting Pronouncements

ASU No. 2016-02, Leases (Topic 842)

XML 26 R14.htm IDEA: XBRL DOCUMENT

1. Organization and Significant Accounting Policies (Tables)

9 Months Ended

Sep. 30, 2018

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Schedule of Investments

Date	Entity	Transaction Description	% Ownership

March 2004	Dougherty’s Holdings, Inc. and subsidiaries (“DHI”or “the Borrowers”)	Acquisition of retail pharmacy		100%

September 2010	ASDS of Orange County, Inc. (“ASDS”),	Holding company for Investment in CRESA Partners of Orange County, L.P. (“CPOC”)		100%

XML 27 R15.htm IDEA: XBRL DOCUMENT

2. Notes Payable (Tables)

9 Months Ended

Sep. 30, 2018

Debt Disclosure [Abstract]

Schedule of notes payable

	September 30, 2018			December 31, 2017
		(Unaudited)			(Audited)

First National Bank of Omaha Credit Facility and Promissory Note secured by certain retail pharmacy assets
Revolving line of credit in the principal amount of $4,000,000 and $4,450,000, interest at LIBOR plus 3.25% (5.24% at September 30, 2018)	$	–		$	3,831,000
Term note OSK VII, LLC principal amount of $3,956,000, interest at LIBOR plus 3.25% (5.36% at September 30, 2018)		3,956,000
Term note in the principal amount of $432,859 at fixed interest rate of 8.11% per annum payable in 36 monthly installments of $13,641. Final payment plus accrued and unpaid interest due in full on April 10, 2020.		242,000			335,000
Term note in the principal amount of $1,827,850 with interest payable at prime plus 2.60% (7.85% at September 30, 2018) per annum payable in monthly installments of $15,232 plus interest, a final payment of $929,157 plus all accrued and unpaid interest due in full on July 10, 2020.		1,249,000			1,371,000
Term note in the principal amount of $1,241,350 with interest payable at prime plus 2.60% (7.85% at September 30, 2018) per annum payable in monthly installments of $10,344 plus interest, a final payment of $638,850 plus all accrued and unpaid interest due in full on January 10, 2020.		786,000			869,000
Term note in the principal amount of $744,100 with interest payable at prime plus 2.38% (7.63% at September 30, 2018) per annum payable in monthly installments of $6,200 plus interest, a final payment of $378,251 plus all accrued and unpaid interest due in full on August 10, 2020.		521,000			570,000
Term note in the principal amount of $305,350 with interest payable at prime plus 2.40% (7.65% at September 30, 2018) per annum payable in monthly installments of $2,545 plus interest, a final payment of $155,220 plus all accrued and unpaid interest due in full on August 10, 2019.		181,000			202,000
Acquisition Notes Payable, unsecured
Notes payable to sellers of acquired pharmacies with varying monthly payments with interest at 5.5% due through September 2018.		–			97,000
Insurance notes payable, secured by the respective insurance policies
Notes payable for the Company’s insurance policy premiums with varying monthly payments due through September 2018. Interest rates vary up to 4.076%		–			170,000
		6,935,000			7,445,000
Less current portion		(5,282,000	)		(4,644,000	)
	$	1,653,000		$	2,801,000

Future maturities of notes payable

2018	$	4,130,000
2019		1,324,000
2020		1,481,000
	$	6,935,000

XML 28 R16.htm IDEA: XBRL DOCUMENT

3. Stock and Share-Based Compensation (Tables)

9 Months Ended

Sep. 30, 2018

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Restricted stock activity

Year of Issuance:	Number of Shares		Fair Value at Date of Grant		Shares Vested		Non-Vested		Cancelled
2013		120,000	$	26,000		115,000		–		5,000
2014		122,100	$	31,000		101,850		–		20,250
2015		150,000	$	39,000		85,000		15,000		50,000
2016		–		–		–		–		–
2017		563,000	$	114,000		111,600		45,000		406,400
2018		80,000	$	11,000		–		80,000		–
		1,035,100	$	221,000		413,450		140,000		481,650

XML 29 R17.htm IDEA: XBRL DOCUMENT

4. Commitments and Contingencies (Tables)

9 Months Ended

Sep. 30, 2018

Commitments and Contingencies Disclosure [Abstract]

Schedule of minimum operating lease payments

2018	$	788,000
2019		806,000
2020		670,000
2021		674,000
2022		685,000
Thereafter		3,372,000
	$	6,995,000

XML 30 R18.htm IDEA: XBRL DOCUMENT

1. Organization and Significant Accounting Policies (Details)	9 Months Ended
	Sep. 30, 2018
Dougherty's Holdings, Inc. [Member]
Ownership percentage	100.00%
Date of investment	Mar. 01, 2004
Transaction description	Acquisition of retail pharmacy
ASDS of Orange County, Inc. [Member]
Ownership percentage	100.00%
Date of investment	Sep. 01, 2010
Transaction description	Holding company for Investment in CRESA Partners of Orange County, L.P. ("CPOC")

XML 31 R19.htm IDEA: XBRL DOCUMENT

1. Organization and Significant Accounting Policies (Details Narrative) - USD ($)	4 Months Ended	9 Months Ended
	May 06, 2017	Sep. 30, 2018	Sep. 30, 2017	Mar. 22, 2019	Dec. 31, 2017	Dec. 31, 2016
Cash received upon disposition of pharmacy		$ 0	$ 274,000
Credit line amount outstanding		3,956,000
Cash and restricted cash		206,000	450,000		$ 389,000	$ 361,000
Working capital		(3,720,000)
Total debt outstanding		6,935,000			$ 7,445,000
Cash provided from operating activities		448,000	602,000
Unrecognized stock based compensation		$ 12,000	$ 116,000
Unvested restricted stock units		140,000	658,500
Antidilutive shares excluded from EPS		140,000	658,500
Revolver [Member]
Interest expense		$ 18,000
Humble Texas Pharmacy [Member]
Cash received upon disposition of pharmacy	$ 274,000
Associated Food Stores [Member]
Letter of credit				$ 825,000

XML 32 R20.htm IDEA: XBRL DOCUMENT

2. Notes Payable (Details - Notes payable) - USD ($)	9 Months Ended
2. Notes Payable (Details - Notes payable) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Notes payable	$ 6,935,000	$ 7,445,000
Notes payable - current	(5,282,000)	(4,644,000)
Notes payable - long term	1,653,000	2,801,000
Revolving Credit Facility [Member]
Notes payable	$ 0	3,831,000
Interest rate description	LIBOR plus 3.25%
Interest rate at period end	5.24%
Term Note 1 [Member]
Notes payable	$ 242,000	$ 335,000
Debt face amount	$ 432,859
Interest rate description	Fixed rate of 8.11%
Interest rate at period end		8.11%
Debt maturity date	Apr. 10, 2020
Debt periodic frequency	monthly
Debt periodic payment	$ 13,641
Term Note 2 [Member]
Notes payable	1,249,000	$ 1,371,000
Debt face amount	$ 1,827,850
Interest rate description	Prime plus 2.6%
Interest rate at period end	7.85%
Debt maturity date	Jul. 10, 2020
Debt periodic frequency	monthly
Debt periodic payment	$ 15,232
Debt baloon payment	929,157
Term Note 3 [Member]
Notes payable	786,000	$ 869,000
Debt face amount	$ 1,241,350
Interest rate description	Prime plus 2.6%
Interest rate at period end		7.85%
Debt maturity date	Jan. 10, 2020
Debt periodic frequency	monthly
Debt periodic payment	$ 10,344
Debt baloon payment	638,850
Term Note 4 [Member]
Notes payable	521,000	$ 570,000
Debt face amount	$ 744,100
Interest rate description	Prime plus 2.38%
Interest rate at period end	7.63%
Debt maturity date	Aug. 10, 2020
Debt periodic frequency	monthly
Debt periodic payment	$ 6,200
Debt baloon payment	378,251
Term Note 5 [Member]
Notes payable	181,000	202,000
Debt face amount	$ 305,350
Interest rate description	Prime plus 2.4%
Interest rate at period end	7.65%
Debt maturity date	Aug. 10, 2019
Debt periodic frequency	monthly
Debt periodic payment	$ 2,545
Debt baloon payment	155,220
Acquisition Notes Payable [Member]
Notes payable	$ 0	97,000
Interest rate description	5.5%
Interest rate at period end	5.50%
Debt maturity date	Sep. 30, 2018
Insurance Notes Payable [Member]
Notes payable	$ 0	$ 170,000
Interest rate description	Rates vary up to 4.076%
Debt maturity date	Sep. 30, 2018

XML 33 R21.htm IDEA: XBRL DOCUMENT

2. Notes Payable (Details - Future debt maturities) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Debt Disclosure [Abstract]
Future maturities 2018	$ 4,130,000
Future maturities 2019	1,324,000
Future maturities 2020	1,481,000
Future maturities total	$ 6,935,000	$ 7,445,000

XML 34 R22.htm IDEA: XBRL DOCUMENT

2. Notes Payable (Details Narrative) - Revolving Credit Facility [Member] - First National Bank [Member]	9 Months Ended
	Sep. 30, 2018 USD ($)
Line of credit collateral	Secured by, but not limited to, the accounts receivable, inventory and fixed assets
Line of credit maximum amount	$ 4,000,000
Line of credit interest rate	LIBOR plus 3.25%
Interest rate at period end	5.36%

XML 35 R23.htm IDEA: XBRL DOCUMENT

3. Stock and Share-Based Compensation (Details) - USD ($)	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Shares non-vested	140,000	658,500
Restricted Stock Units (RSUs) [Member]
Number of shares	1,035,100
Fair value at date of grant	$ 221,000
Shares vested	413,450
Shares non-vested	140,000
Shares cancelled	481,650
RSU 1 [Member]
Date of grant	2013
Number of shares	120,000
Fair value at date of grant	$ 26,000
Shares vested	115,000
Shares non-vested	0
Shares cancelled	5,000
RSU 2 [Member]
Date of grant	2014
Number of shares	122,100
Fair value at date of grant	$ 31,000
Shares vested	101,850
Shares non-vested	0
Shares cancelled	20,250
RSU 3 [Member]
Date of grant	2015
Number of shares	150,000
Fair value at date of grant	$ 39,000
Shares vested	85,000
Shares non-vested	15,000
Shares cancelled	50,000
RSU 4 [Member]
Date of grant	2016
Number of shares	0
Fair value at date of grant	$ 0
Shares vested	0
Shares non-vested	0
Shares cancelled	0
RSU 5 [Member]
Date of grant	2017
Number of shares	563,000
Fair value at date of grant	$ 114,000
Shares vested	111,600
Shares non-vested	45,000
Shares cancelled	406,400
RSU 6 [Member]
Date of grant	2018
Number of shares	80,000
Fair value at date of grant	$ 11,000
Shares vested	0
Shares non-vested	80,000
Shares cancelled	0

XML 36 R24.htm IDEA: XBRL DOCUMENT

4. Commitments and Contingencies (Details - Minimum lease payments)	Sep. 30, 2018 USD ($)
Commitments and Contingencies Disclosure [Abstract]
Minimum lease payment 2018	$ 788,000
Minimum lease payment 2019	806,000
Minimum lease payment 2020	670,000
Minimum lease payment 2021	674,000
Minimum lease payment 2022	685,000
Minimum lease payment thereafter	3,372,000
Future minimum operating lease payments	$ 6,995,000

XML 37 R25.htm IDEA: XBRL DOCUMENT

5. Related Party Transactions (Details Narrative) - USD ($)	3 Months Ended	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2018
Directors [Member]
Director fees	$ 5,000	$ 33,000
Chairman [Member]
Management fees	$ 30,000	$ 90,000

EXCEL 38 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 39 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 40 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 41 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.1 html 60 150 1 false 24 0 false 4 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://dougherty.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - Consolidated Balance Sheets (Unaudited) Sheet http://dougherty.com/role/BalanceSheets Consolidated Balance Sheets (Unaudited) Statements 2 false false R3.htm 00000003 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://dougherty.com/role/BalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Consolidated Statements of Operations (Unaudited) Sheet http://dougherty.com/role/StatementsOfOperations Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Consolidated Statements of Cash Flows (Unaudited) Sheet http://dougherty.com/role/StatementsOfCashFlows Consolidated Statements of Cash Flows (Unaudited) Statements 5 false false R6.htm 00000006 - Disclosure - Reconciliation of Cash to the Consolidated Balance Sheets (Unaudited) Sheet http://dougherty.com/role/ReconciliationOfCashToConsolidatedBalanceSheets Reconciliation of Cash to the Consolidated Balance Sheets (Unaudited) Notes 6 false false R7.htm 00000007 - Disclosure - 1. Organization and Significant Accounting Policies Sheet http://dougherty.com/role/OrganizationAndSignificantAccountingPolicies 1. Organization and Significant Accounting Policies Notes 7 false false R8.htm 00000008 - Disclosure - 2. Notes Payable Notes http://dougherty.com/role/NotesPayable 2. Notes Payable Notes 8 false false R9.htm 00000009 - Disclosure - 3. Stock and Share-Based Compensation Sheet http://dougherty.com/role/StockAndShare-basedCompensation 3. Stock and Share-Based Compensation Notes 9 false false R10.htm 00000010 - Disclosure - 4. Commitments and Contingencies Sheet http://dougherty.com/role/CommitmentsAndContingencies 4. Commitments and Contingencies Notes 10 false false R11.htm 00000011 - Disclosure - 5. Related Party Transactions Sheet http://dougherty.com/role/RelatedPartyTransactions 5. Related Party Transactions Notes 11 false false R12.htm 00000012 - Disclosure - 6. Subsequent Events Sheet http://dougherty.com/role/SubsequentEvents 6. Subsequent Events Notes 12 false false R13.htm 00000013 - Disclosure - 1. Organization and Significant Accounting Policies (Policies) Sheet http://dougherty.com/role/OrganizationAndSignificantAccountingPoliciesPolicies 1. Organization and Significant Accounting Policies (Policies) Policies http://dougherty.com/role/OrganizationAndSignificantAccountingPolicies 13 false false R14.htm 00000014 - Disclosure - 1. Organization and Significant Accounting Policies (Tables) Sheet http://dougherty.com/role/OrganizationAndSignificantAccountingPoliciesTables 1. Organization and Significant Accounting Policies (Tables) Tables http://dougherty.com/role/OrganizationAndSignificantAccountingPolicies 14 false false R15.htm 00000015 - Disclosure - 2. Notes Payable (Tables) Notes http://dougherty.com/role/NotesPayableTables 2. Notes Payable (Tables) Tables http://dougherty.com/role/NotesPayable 15 false false R16.htm 00000016 - Disclosure - 3. Stock and Share-Based Compensation (Tables) Sheet http://dougherty.com/role/StockAndShare-basedCompensationTables 3. Stock and Share-Based Compensation (Tables) Tables http://dougherty.com/role/StockAndShare-basedCompensation 16 false false R17.htm 00000017 - Disclosure - 4. Commitments and Contingencies (Tables) Sheet http://dougherty.com/role/CommitmentsAndContingenciesTables 4. Commitments and Contingencies (Tables) Tables http://dougherty.com/role/CommitmentsAndContingencies 17 false false R18.htm 00000018 - Disclosure - 1. Organization and Significant Accounting Policies (Details) Sheet http://dougherty.com/role/OrganizationAndSignificantAccountingPoliciesDetails 1. Organization and Significant Accounting Policies (Details) Details http://dougherty.com/role/OrganizationAndSignificantAccountingPoliciesTables 18 false false R19.htm 00000019 - Disclosure - 1. Organization and Significant Accounting Policies (Details Narrative) Sheet http://dougherty.com/role/OrganizationAndSignificantAccountingPoliciesDetailsNarrative 1. Organization and Significant Accounting Policies (Details Narrative) Details http://dougherty.com/role/OrganizationAndSignificantAccountingPoliciesTables 19 false false R20.htm 00000020 - Disclosure - 2. Notes Payable (Details - Notes payable) Notes http://dougherty.com/role/NotesPayableDetails-NotesPayable 2. Notes Payable (Details - Notes payable) Details http://dougherty.com/role/NotesPayableTables 20 false false R21.htm 00000021 - Disclosure - 2. Notes Payable (Details - Future debt maturities) Notes http://dougherty.com/role/NotesPayableDetails-FutureDebtMaturities 2. Notes Payable (Details - Future debt maturities) Details http://dougherty.com/role/NotesPayableTables 21 false false R22.htm 00000022 - Disclosure - 2. Notes Payable (Details Narrative) Notes http://dougherty.com/role/NotesPayableDetailsNarrative 2. Notes Payable (Details Narrative) Details http://dougherty.com/role/NotesPayableTables 22 false false R23.htm 00000023 - Disclosure - 3. Stock and Share-Based Compensation (Details) Sheet http://dougherty.com/role/StockAndShare-basedCompensationDetails 3. Stock and Share-Based Compensation (Details) Details http://dougherty.com/role/StockAndShare-basedCompensationTables 23 false false R24.htm 00000024 - Disclosure - 4. Commitments and Contingencies (Details - Minimum lease payments) Sheet http://dougherty.com/role/CommitmentsAndContingenciesDetails-MinimumLeasePayments 4. Commitments and Contingencies (Details - Minimum lease payments) Details http://dougherty.com/role/CommitmentsAndContingenciesTables 24 false false R25.htm 00000025 - Disclosure - 5. Related Party Transactions (Details Narrative) Sheet http://dougherty.com/role/RelatedPartyTransactionsDetailsNarrative 5. Related Party Transactions (Details Narrative) Details http://dougherty.com/role/RelatedPartyTransactions 25 false false All Reports Book All Reports mydp-20180930.xml mydp-20180930.xsd mydp-20180930_cal.xml mydp-20180930_def.xml mydp-20180930_lab.xml mydp-20180930_pre.xml http://fasb.org/srt/2018-01-31 http://fasb.org/us-gaap/2018-01-31 http://xbrl.sec.gov/dei/2018-01-31 true true ZIP 43 0001683168-19-001220-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001683168-19-001220-xbrl.zip M4$L#!!0 ( $QNG4ZXD#N>&%< -^' P 1 ;7ED<"TR,#$X,#DS,"YX M;6SM?>MSVT:R[_=;=?X'7)_DW*2*I/DF92>Y)4MVUKN.I2/9NV?OERV0&(I8 M@P 7#\G:O_[V8P88@" )\"&2$E*[B4@",ST]/3T]W3V__N7_?I\YQKWP ]MS M?WW5:C1?&<(=>Y;MWOWZZNMM_?SVXN/'5\;__>T__IF-ZQ_=B??6^&S.Q!OC=^$*WPP]_ZWQ5].)\!OO@^T(W[CP9G-'A )^X)[> M&-U&NS\RZO4"[?Y5N);G?[WY&+<[#O'QX>&JYW;SYX_K>@,?:*-7?K M1?Y8Q&U97G0W%7[X^(]_=7YL7[:;K6'SK--L?)_ ."[-$!Z![\[@IV87?S_[ MTNJ_Z?7>M%K_KV!_H1E&0=Q?\WM3_L.O__)]Y#OV&_RW 7/A!F^^!_:OK[0A M/G0:GG_WNMULME[_SQ^?;L=3,3/KMAN$ICL6K]1;CNU^RWNO=79V]II^58\N M/(F=JSXZK_'GD1DD+2.!*YY?H 1^M<+X!?WAWFO^,?6HG?MHGQ^UU:.6R#P7 MB''CSKM_#3^\QEFK-UOU3DL][HO)4I+[K^%7]: =>-UV:[!J?/R$>B$*ZG>F M.8]?F)C!B!Z6/^00 [_XGB."W'?HEYR77,]UHUD^75;HOPX?Y^(U/%2'IX1O MC^/WUK^4?@%HP*_SJ:-?Y$;^H_Y4R)_Q-<&Z=<"/USL!K[,Z>&/OU]> MQ\_&JQ26^>RU6J2OU/)#D7T3T,*X$1.#I/W-E&1@]FC-Z\FJ#JQ7\F<]O"7R8VZ$*B4J1F2+'MXN-?7OT&BJ'5'#:;[;-?7F=?3KI[G=N?[&T.L^M9 MBU3 ,O5#5&F_)<-1+26_+;P&ZE=["<>==&^E7E'?IPA07TJ6+N?S>7 U055; M;W;KK=:)\9:58/A;,H"X"_G+3IETF@*H,2DC27MATJ#>:J-".5DFR0'LATE2 MK0TTM38X2:E*J;7!)FIM\ 1JK7_JPMC?IS#&*_84!3"U8O>OUJ3J_,>$+RPX_F&/; >I/>Y[EX-Y\\MR[4/BS2S$*O\!) MBR=<_;IRZ,]<#*115XG!\8K!7NWN? W_V0O%M?EHCAS1?LY33RI_<; O9,U7 MD_VB5W;G)4UVY^"3?=B574WV"UK9W9TF3W#C[9 MAUW9U62_H)7=?TF3W3_X9!]V95>3_8)6]N E3?;@X)-]V)5=3?8+6MG#ES39 MPX-/]F%7=C79SV=E+T^BK8(B!YGX(T\&+B4OE:N]DIB-OWUU[3"X MN?WZ/&3G_,'TK;R,XA5CKD2HI,H!SK6>I;B0CDE&5PE&><%X)CZZ)8)1.>4V M%HQGXHQ;(AB5]VUCP7@F7KJOSG4G[(2AB> MQ7(?/*]2*(/C6CU);8:8SZ<)C9^MS5">ST]1FZ'*G#ZRS.G#Z[,JKG*4<97C MU-,KY*>*JQQ17.7(I"-:IM]NQDSP(O+&-S/S@>:B,?7'BRB?PPS<76!)0 M^'.4#ZR+J7O.EP[X@-N.G)2];CN9TEN]>K.OA.!/T6SDB"_BNQE<3\V9.7XF MSO!+.YA[@>G\[GO1_,(Q@P"Z&9.[1).(9:,_J/[8M+(83NNA F[L%Q/^\Q"> MI4ZW]# /O7"K,^$&42^^$W6M7T#SZC&U$_I+K"U)>W? M3DW0UDN[D$R@AS;N ^B[7M*/9=^#N"WR%M_]C%5NL1SUHK25X$&6QKQ6M4XO MA>O-;'==M^OYDNTWKV'U>XH+!1AZ+?PQB/B:69O#G\7G# /C'!._$78.U>%=5TKU4%7[_3V" TO=1Z]>,C^ZX\]_$8^%>]?5V-+6].XNO7&$N@,/TH5[:37K_\WMZZ_G-7M-2_T]*X+"[>NJ M9&EK>G?G\*N%3WQPS+O"W4Q,)Q#<0ZH!O>6+R/?Q:SL8F\[?A>F7'4M=H=&M M:BU' /C)&S'W_-!V[[CZ>N%>_X[K<5UKB[U2F?L+(.C.\XL+W6?/K9OCL7!0 MHPC+H%;T[E/-YHD),X2G]P-\5WR@_]U)B\A"2\N[0_Z7ZPS_SNLN;BEG'KW9 MS'/)%<6Z_RH*T03'[*M4OYFJT08J)?I!;AF&)<;V#"3VUU(=9UF)S6T[3LM,,ARG9Z/QWB,#F[$6-CW M"([R68121VW,YU9OV$O1L*J7;2DJ-!.M_J"S,457(5@1R8/!#CC4;@U3Y"SO M8CMBBHEIM[10"5]/IG ^0DVE6W9HA&QI.DM*"C$B[2R*TC$1_<>OH4- M%3BUN4@,>]U4YWJK97LL-N^]?KMPC]>^F)NV]?[[',[06T_T(*WS>W P1*>?O^OR)[CJ]MP[JS7 MS\CL\DZV):C8MMK,;!UE*/KH@CU\9P,#61;AD???QTZ$)O+OGF<]V(ZSN3;M M#,\RNFU];[NBL)@"&IYEM6]Y"B_%1, *MKZ8W^.7X PXWN$^O+*'[>DIQJMF M,ZTQRU'%CVS,C>&@-\C1G<5[*;:6VOUVH6ZDY2JQ#+>V1(=G_5S+.-W^YE04 M,T5:[7S[?"T5?B2L3[8Y0@>^+;;?FX<+=.3WL!4IQ;:A]MEFI"#2Y:[$H]5I MI\4CI_$-^R_F?6AURG:_0VD8]ONMM"FPEOD[%(!A*[,T"_0N316=39O/?;_7 MR36$]-8WI:#@'MELE:<@X=+F0V]V6MUEO"_984%+ZNQL4+1#.*OP]D?^Q;^: M3K3Y)*>/0-EF-^RYT)#+]:PY5+<;<-KHRC:[2;>%39CBW9Y;ELT7/J[A4/K1 MO3#G=FAN;@[WF^V,/"_I80M""OI7VNW6)H3M5T$CN,[9,7" MH6A=3[N@;,.#5%G2TMO1M>E?^1BF%1;)U[7P*:17F'772^*P16+8)+NMU M=[3F,G,9KZ(S*T4 MV79D[FPYMKNM5KO5[^82MFH9E""FL*"UX:C0Z;3RSRNEB-G5@FQWFL,U["DF M_KM=D>WVV6 -H\J0M:.MD/>;)$'[VPK\+H'CLW;DXW20# M5W.Z][71@0038=,.EB>A]6@8M#8Q#!G4ZA^>0^=N:%NV$X7V/70\CGPZE'&8 M4UB8:X.M1R$U?C51[@VU$Y_/,"A4-$ETK4YJ9?,P=D'=DPTY<]>KV)#[E)JW MYR$C+ME'-PA]3LPUQWFCR%=K.26[5PEUM],>]L[TN'!^S_NAL%. PM:P/0"6 M'XK$;A$2P?CL'([$7@$2!]UNJWDP"OL%*.PT>SO@X4>\T0H*]P8.(1CG*IH0 MOZKB_0?[.]AN>!_ \";&L-%J_;B,S(7NGXS:&/?_VK=GPI@[46"T&_TCI+1[ M,I3VF_VA$\G$S%&LZ?8L:L8X>N/8HUFK]TM,IP<^G8^ M.'EZ+V1\+1_0L-4ZE@&5L=66#:@)"V78.Y81+9^B1=/N-$94QA)<-:)^Y_A' MM&@YKAS1"_&* M"-"QC[#(WML9#-N]HA;:T8VPR#[=ZO7:[3W,H;K0A.V=NY:\_/!)F(&X&CGV M'<5= [F2;1';[(W$O MS/CH8M-?'KR-,TDZ[>[N&1"3M<]!3WVQV;4.''9WF'_7;E>$J8$S"#CL25>3 MWQ%VK^1>F)2\ISVP\\OK;(.[ZT@SAQ'>:W\=:<9MJ[?/CC13M=7?9T>:X=D: M[+,CW8P<+N](275^GM.Y#\_>"93>=X_)(U)Y4_(3I\TE.C\@F*0O4].5N4[4 M7?#1Y]#"/G;V;F$:MWA-)ZJFRLKAI!&]74KD3TVA8">4I64:GRL7"EE&+ M[EI5K-R!973*7/SLR0X6"'C_?6[[YN)UOB>PA8:M_DYVG4*#.TY6;F#W[&B# M>19,*VSAM)OM2M1*&S.['R+#A6V$CI-OO=2M .8I"4XI@L1[BP MZW\P;9]@:LZI&J"7$S_+SWS(W?=R,A,9+J!<]_LDNDBF<*=U9$07R8#JG!T9 MT462FHZ*X"(Y2BT)@'H\5!?*.SH.@2Y[^LA1)^UM1K+_,V",=/(YHF*QVP P M97%%GHSJHV+7QI@D+Y-=6YQ.*]YM?DBM>+=E2D+%O^/VMI\6[XH?7RO9.XV4 M@U/@WZZ2,(_%[KN:8_UGV[VC;.W@0Q1&OOC#=NU9-)/]:)5/=WI]8##,5#;= MGI3M1O?1_?+@83,;0TL.,R66-^U_ZW%@%OU6(Z&:E]N,)*9@V[%\\")_RZ%T MMQI*3,#6(['OMYR43/K"Q@1L-Y(OH&&$.0F+GGUS_%B=3&7/30G8;B ;S\/9 MV383D24:5+0M44YD4=E+VQ?CT/.##T*4=5''[Q;Q)V9+IJTD9#=T#W9 =V\; MLJ]];R*"P,9"0GA;":CTS7$HT6T#V41)KE],3=N?F6Z1:ZS9&@]%R-GI()9- M08E!='8QB$^V*V#5,3[:MA7X.MF:MWFM;TI!L8)#PTZV!N!Z"E)5B=A:W,ZC MV,Q,34X'&])0&,&]# V6L-^\=T,P8F^A!>==%"#3BBJ]5[^!W2M^>;VDE9R[ M8PF.>5F]NH@&CZ7:NO5FIXYE(G+[V"4!&HX[WF!KXJ]K.U8SH#@"QXN1[=+I MXE;,3<1Z=1X31.XO<. (8.'BR>%2!&/?IE/$#EAU/H:32D#UVQ!
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end